<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Proteome Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Proteome Res</journal-id>
    <journal-id journal-id-type="publisher-id">pr</journal-id>
    <journal-id journal-id-type="coden">jprobs</journal-id>
    <journal-title-group>
      <journal-title>Journal of Proteome Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1535-3893</issn>
    <issn pub-type="epub">1535-3907</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11301774</article-id>
    <article-id pub-id-type="pmid">38932690</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jproteome.4c00188</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>A Handle on Mass
Coincidence Errors in <italic>De
Novo</italic> Sequencing of Antibodies by Bottom-up Proteomics</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0594-0993</contrib-id>
        <name>
          <surname>Schulte</surname>
          <given-names>Douwe</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9310-8226</contrib-id>
        <name>
          <surname>Snijder</surname>
          <given-names>Joost</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
      </contrib>
      <aff id="aff1">Biomolecular Mass Spectrometry
and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht
Institute of Pharmaceutical Sciences, <institution>Utrecht
University</institution>, Padualaan 8, Utrecht 3584
CH, <country>The Netherlands</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>j.snijder@uu.nl</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>27</day>
      <month>06</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>02</day>
      <month>08</month>
      <year>2024</year>
    </pub-date>
    <volume>23</volume>
    <issue>8</issue>
    <fpage>3552</fpage>
    <lpage>3559</lpage>
    <history>
      <date date-type="received">
        <day>11</day>
        <month>03</month>
        <year>2024</year>
      </date>
      <date date-type="accepted">
        <day>20</day>
        <month>06</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>29</day>
        <month>05</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2024 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2024</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0006" id="ab-tgr1"/>
      </p>
      <p>Antibody sequences
can be determined at 99% accuracy directly from
the polypeptide product by using bottom-up proteomics techniques.
Sequencing accuracy at the peptide level is limited by the isobaric
residues leucine and isoleucine, incomplete fragmentation spectra
in which the order of two or more residues remains ambiguous due to
lacking fragment ions for the intermediate positions, and isobaric
combinations of amino acids, of potentially different lengths, for
example, GG = N and GA = Q. Here, we present several updates to Stitch
(v1.5), which performs template-based assembly of <italic>de novo</italic> peptides to reconstruct antibody sequences. This version introduces
a mass-based alignment algorithm that explicitly accounts for mass
coincidence errors. In addition, it incorporates a postprocessing
procedure to assign I/L residues based on secondary fragments (satellite
ions, <italic>i.e.</italic>, <italic>w-</italic>ions). Moreover, evidence
for sequence assignments can now be directly evaluated with the addition
of an integrated spectrum viewer. Lastly, input data from a wider
selection of <italic>de novo</italic> peptide sequencing algorithms
are allowed, now including Casanovo, PEAKS, Novor.Cloud, pNovo, and
MaxNovo, in addition to flat text and FASTA. Combined, these changes
make Stitch compatible with a larger range of data processing pipelines
and improve its tolerance to peptide-level sequencing errors.</p>
    </abstract>
    <kwd-group>
      <kwd>mass spectrometry</kwd>
      <kwd><italic>de novo</italic> sequencing</kwd>
      <kwd>sequence assembly</kwd>
      <kwd>antibodies</kwd>
      <kwd>alignment</kwd>
      <kwd>isobaric</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>HORIZON EUROPE European Research Council</institution>
            <institution-id institution-id-type="doi">10.13039/100019180</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>101077640</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Exacte en Natuurwetenschappen</institution>
            <institution-id institution-id-type="doi">10.13039/501100024870</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>024.002.009</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>pr4c00188</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>pr4c00188</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Antibodies are essential components of
the adaptive immune system
that can recognize a vast array of antigens in the fight against pathogens
or in autoimmune disease.<sup><xref ref-type="bibr" rid="ref1">1</xref>−<xref ref-type="bibr" rid="ref4">4</xref></sup> The diversity of antigens recognized by antibodies
is mirrored by the diversity of the antibody sequences. This diversity
is generated by somatic recombination and hypermutation of the paired
heavy and light chains, taking place in singular B cells. Studying
these unique antibody sequences therefore is crucial to understanding
the immune response in health and disease and to developing diagnostics,
therapeutics, and affinity reagents for life science research based
on antibody-mediated recognition and binding of target antigens.</p>
    <p>Established methods for antibody sequencing target the coding mRNA
in single B cells.<sup><xref ref-type="bibr" rid="ref5">5</xref>−<xref ref-type="bibr" rid="ref12">12</xref></sup> While these methods have laid the foundation for our current understanding
of the antibody response, they do not directly access the functional
secreted products found in bodily fluids in the same way as they are
probed in common serological assays (to determine the binding and
neutralization titers following natural infection or immunization).
Additionally, B cells reside in the spleen, bone marrow, and blood,
of which only the latter population can be easily sampled in human
subjects. In contrast, mass spectrometry-based methods can probe specific
antibody sequences directly from the secreted polypeptide product,
thereby circumventing the need to sample the antibody-producing B-cell
clone and providing a direct glimpse into the so-called serum compartment
of the immunoglobulin repertoire.<sup><xref ref-type="bibr" rid="ref13">13</xref>−<xref ref-type="bibr" rid="ref26">26</xref></sup></p>
    <p>Using a bottom-up proteomics approach, accurate peptide sequences
can be determined and assembled into complete heavy- and light-chain
sequences. We have recently developed the software tool Stitch to
perform template-based assembly of peptide sequences against the coding
gene segments of antibodies available in immunogenetics databases.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Stitch has been shown to enable the accurate
reconstruction of monoclonal antibody sequences, as well as the sequencing
of isolated Fab fragments from patient serum, M-proteins in monoclonal
gammopathies, antibody light chains from urine, and the profiling
of whole IgG from COVID-19 patient sera.<sup><xref ref-type="bibr" rid="ref13">13</xref>−<xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup> Sequence accuracies of ∼99% can be obtained,
which is sufficient to reverse engineer functional antibody products.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> Remaining sequencing errors stem in large parts from common mass
coincidences of isobaric residues like leucine/isoleucine but also
from incomplete fragmentation spectra in which the order of two or
more residues remains ambiguous due to lacking fragment ions for the
intermediate positions. Likewise, different combinations of amino
acids, of potentially different lengths, can also coincide to the
same mass (e.g., GG=N, GA=Q). In addition to limiting
the accuracy of the input peptide sequences, these mass coincidence
errors may also hamper proper assembly of the short peptides against
the antibody template sequences.</p>
    <p>Here, we discuss several recent
updates to Stitch (v1.1 up to and
including v1.5) in light of common MS-based <italic>de novo</italic> sequencing errors. These updates include a mass-based alignment
algorithm (akin to Meta-SPS-contig<sup><xref ref-type="bibr" rid="ref30">30</xref></sup>),
a post-processing procedure to assign I/L residues based on secondary
fragments, a built-in spectrum viewer, a graph-based analysis that
tracks the connectivity between identified sequence variants, and
the ability to use a wider selection of <italic>de novo</italic> peptide
sequencing programs as input, including Casanovo, MaxNovo, Novor.Cloud,
PEAKS, and pNovo.<sup><xref ref-type="bibr" rid="ref31">31</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> Combined, these changes make Stitch compatible with a larger range
of data processing pipelines and improve its tolerance to peptide-level
sequencing errors.</p>
  </sec>
  <sec id="sec2">
    <title>Methods</title>
    <sec id="sec2.1">
      <title>Mass Coincidence Rate</title>
      <p>The mass coincidence rates over
different precisions and mass ranges (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A,B) were calculated by generating all possible
amino acid sequences from the canonical amino acids for each mass
range (without rotations), including the following modifications:
Carbamidomethyl (fixed on C), Oxidation (variable on WHM), Deamidated
(variable on NQ), Glu → pyro-Glu (variable on N-term E), and
Gln → pyro-Glu (variable on N-term Q). For each of these sets
of possible sequences, the number of unique masses was calculated
by going through the possible sets sorted on mass and greedily combining
any set with the previous if within the given precision.</p>
    </sec>
    <sec id="sec2.2">
      <title>Smith-Waterman
Comparison to Mass-Based Alignment</title>
      <p>The
comparison between Smith–Waterman alignment (SWA) and mass-based
alignment (MBA) (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A) was made by running Stitch with different PEAKS ALC peptide cutoff
scores. The other parameters used were enforce unique 0.9, cutoff
score template matching 5, cutoff score recombination 5, with the
default templates for <italic>Homo sapiens</italic> heavy
and light chains, and common contaminants. The identity was determined
using a version of MBA by comparing the consensus sequence as given
by these runs to the known sequence. The coverage was determined by
counting the fractions of positions that had at least one peptide
matching as given in the Stitch FASTA export.</p>
      <p>The average scores
for each ALC bin (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B) were calculated using the Herceptin data at PEAKS ALC cutoff
50 from <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A.
The score was normalized by dividing the absolute score by the length
of each peptide it matched on the template. These scores were grouped
by ALC of the peptide, and the average and standard deviation were
calculated.</p>
    </sec>
    <sec id="sec2.3">
      <title>Accuracy/Error Estimates</title>
      <p>The likelihood
of a given
number of mistakes (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>) was calculated following a simple binomial model, in which
the probability <italic>P</italic>(<italic>C</italic>, <italic>T</italic>) of obtaining <italic>C</italic> correct amino acids in a sequence
of length <italic>T,</italic> with a given accuracy <italic>a</italic>, equals <italic>a</italic><sup><italic>C</italic></sup> × (1
– <italic>a</italic>)<sup><italic>T</italic>−<italic>C</italic></sup>, which can be simplified to <italic>a</italic><sup><italic>T</italic></sup> when <italic>C</italic> equals <italic>T</italic>, meaning no mistakes are made, which can then be solved for <italic>a</italic> as <inline-formula id="d34e285"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_m001.gif"/></inline-formula>.</p>
    </sec>
    <sec id="sec2.4">
      <title>Accuracy
of I/L Assignments</title>
      <p>The accuracy at I/L positions
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B) was determined
by running Stitch with the same data as the SWA vs MBA comparison,
with PEAKS cutoff ALC 95, enforce unique 0.9, template matching and
recombine cutoff score 10, mass-based alignment, the default templates
for <italic>Homo sapiens</italic> heavy and light chain,
and common contaminants, the raw data, and by turning on XleDisambiguation
on the input file. For each I/L location, the known true sequence,
Stitch outcome, and germline sequence were compared.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Results</title>
    <p>Stitch assembles peptides from <italic>de novo</italic> sequencing
programs for bottom-up LC-MS/MS data in the correct framework of the
heavy and light chains of an antibody. An outline of the assembly
and processing performed by Stitch, including the new features described
here, is presented in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. The previously published version of Stitch was already able
to handle PEAKS, FASTA, and plain text data, which is now extended
to include the output from Casanovo, MaxNovo, Novor.Cloud, and pNovo.<sup><xref ref-type="bibr" rid="ref31">31</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> These peptides are aligned to the germline sequences of the corresponding
gene segments (V/J/C) for the appropriate species and placed when
the alignment score exceeds a user-defined cutoff. The consensus sequence
for a single template is made from all placed peptides, weighed for
the confidence and abundance of the individually placed peptides as
reported by the peptide <italic>de novo</italic> sequencing programs.
This procedure robustly places peptide reads in the correct framework
of the full antibody sequence except for the hypervariable Complementarity
Determining Region 3 of the heavy chain (CDRH3). CDRH3 is formed by
the junction of three coding gene segments V, D, and J, of which D
is exceptionally short and variable, such that germline sequences
do not provide a functional template to guide the assembly. Instead,
Stitch extends the flanking V- and J-segments with a user-defined
number of wildcard “X” characters, such that overhanging
reads from the V- and J-segments can be used to extend the consensus
sequence into the CDRH3 region. The resulting overhanging V- and J-sequences
are then aligned to find the overlap from both sides to reconstruct
CDRH3. In contrast, CDR3 of the light chain is encoded only with V-
and J-segments and can typically be reconstructed from the first-order
template matching step alone. These consensus sequences of the recombined
V- and J-segments are then used for a second template matching step
to reconstruct the final consensus sequence of the antibody. It should
be noted that this procedure is only suitable for monoclonal antibodies
(although it is tolerant to a moderate background of polyclonal sequences).<sup><xref ref-type="bibr" rid="ref13">13</xref>−<xref ref-type="bibr" rid="ref15">15</xref></sup> The reconstruction of CDRH3 from disperse polyclonal mixtures currently
requires manual curation of the candidate sequences. The template-based
assembly (and recombination) results of Stitch are written out as
an interactive report where all peptide alignments can be inspected,
and overview statistics like total score/area are collected for every
template sequence. To aid in the analysis of disperse polyclonal mixtures,
this new version of Stitch introduces the so-called “variant
graph”, which shows how co-occurring sequence variations in
reference to the templates are connected by peptide reads.</p>
    <fig id="fig1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Overview of
the program Stitch.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0001" id="gr1" position="float"/>
    </fig>
    <p>We also introduced a
fundamentally different alignment algorithm
for the placement of input reads against template sequences. We previously
used a modified version of the Smith–Waterman algorithm (SWA)
using a matrix based on BLOSUM62.<sup><xref ref-type="bibr" rid="ref39">39</xref>−<xref ref-type="bibr" rid="ref41">41</xref></sup> The SWA only accounts
for mismatches between input reads and template sequences that stem
from evolutionary processes like somatic hypermutation observed in
mature antibody sequences compared to the germline precursors. In
our experimental data, however, these mismatches are further convoluted,
with errors inherent to an MS-based approach to peptide sequencing.</p>
    <p>To illustrate the sequencing errors that MS is prone to, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A plots the residue masses of the 20 common amino acids (with
common modifications) on a scale of 50 to 200 Da, also including the
amino acid combinations that fall within this range. Considering that
mass analyzers in current proteomics setups typically operate within
a precision range of 0.01–0.50 Da, we can broadly distinguish
between four categories of MS-based sequencing errors. The first category
is the isobaric residues isoleucine and leucine, which simply have
identical masses and cannot be distinguished without the presence
of secondary fragment ions (as further discussed below). The second
category of common MS-based errors includes larger isobaric <italic>sets</italic> of amino acids, where different combinations of residues
amount to identical masses and cannot be distinguished. This second
category stems from missing fragment ions in the MS/MS spectra. There
are three subcategories of errors in this second category: (a) simple
rotations within a set (e.g., AS = SA), b) isobaric sets (e.g., AS
= GT), and (c) isobaric sets of different lengths (e.g., N = GG, Q
= GA). For sets of three residues or more, combinations of these subcategories
may occur. The third category of common MS-based errors includes (modified)
residues that are not strictly identical in mass but are so similar
that they cannot be distinguished, given the experimental precision
limits of the mass analyzer. For instance, the mass difference between
K and Q is 0.036 Da, between M<sup>ox</sup> and F 0.033 Da. This third
category of MS-based errors can be eliminated with the use of a high-precision
mass analyzer (TOF, FT-MS), but it poses a significant limitation
to <italic>de novo</italic> sequencing at lower precision (ion trap).
The fourth category of common MS-based errors does not necessarily
stem from analytical limitations but rather from artifacts of the
sample processing pipeline in the form of deamidation of Q and especially
N, converting these residues to E and D, respectively.</p>
    <fig id="fig2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Mass coincidence errors
in de novo peptide sequencing. (A) All
possible amino acid sequences up to 200 Da, including common modifications
(carbamidomethyl fixed on C, pyro-Glu, deamidation on N and Q, and
oxidation on M and H). (B) The fraction of sequences that can be told
apart (specificity) is based on the precision in Da and the upper
mass limit (not counting rotations). (C) Illustration of how the mass-based
alignment provides a better handle on mass coincidence errors.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0002" id="gr2" position="float"/>
    </fig>
    <p><xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B illustrates
how these common MS-based errors accumulate as a function of precision
for progressively larger mass intervals (i.e., a higher number of
missing fragments). A few obvious but fundamental requirements and
limitations for <italic>de novo</italic> peptide sequencing can be
observed from this “survival” analysis, showing what
fraction of possible unique residues (or residue combinations) can
be distinguished based on their mass, not counting rotations. First,
it is of the utmost importance to achieve complete fragmentation as
category 2 errors (isobaric subsets) readily accumulate over larger
mass intervals. Second, category 3 errors (similar residue masses)
can be eliminated with high precision mass analyzers. Important to
note is that the required precision to eliminate category 3 errors
is readily achieved on modern mass analyzers for small peptide fragments
with low charge states but that this becomes a significant limitation
for larger fragments with higher charge states in middle- and top-down
approaches. Considering these common MS-based errors, we propose here
a modification of the SWA to perform the template-based assembly for
antibody sequencing.</p>
    <p>One of the most important drawbacks in
the context of these MS-based
errors is that in SWA, a substitution can only be a single amino acid
to another single amino acid while the category 2 errors affect multiple
consecutive residues. The new mass-based alignment we devised considers
these errors by aligning not only single amino acids but also larger
sets, illustrated in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C. It does this by supplementing the alignment steps looked
for in SWA (i.e., match/mismatch/insertion/deletion), with two additional
steps: rotation and isobaric. These last two steps can be of length
up to <italic>N</italic> steps on both the template and peptide (e.g.,
match 2 amino acids on the template with 3 on the input peptide).
With this addition, the category 2 errors, up to N amino acids, can
easily be found. The score for each aligned set of amino acids is
looked up in a premade two-dimensional array with the same modified
BLOSUM62 base matrix in the top left and all category 2 errors given
a nonzero score in the array based on their mass identity. It is important
for the behavior of the alignment that these rotations and isobaric
matches score lower than any direct match. Hence, rotations score
3 per amino acid involved and isobaric matches score 2 per the maximum
number of amino acids involved. The alignment algorithm looks for
any nonzero score in the set of steps of up to <italic>N</italic> residues,
alongside the normal cases for SWA, and the highest scoring of the
possible steps is chosen. This approach is similar to Meta-SPS contig,
with the main difference that alignment and assembly is performed
on the level of the output peptide sequences, rather than the MS/MS
data itself.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup></p>
    <p>Use of the mass-based
alignment (MBA) versus SWA improves the tolerance
to mass coincidence errors during template-based assembly. This difference
is illustrated in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> using PEAKS input data for the two monoclonal antibodies
Herceptin and F59. PEAKS provides a peptide-level average local confidence
(ALC) score between 0 and 99, where peptides with a lower ALC typically
miss more fragment ions to support the given sequence. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A shows how the average length-normalized alignment score
during the assembly develops as a function of the ALC cutoff for MBA
vs SWA. By design, the alignment scores are consistently higher using
MBA vs SWA, the margin illustrating just how common mass coincidence
errors are in the input data. The higher degrees of freedom in MBA
evidently allow for better placement of the input reads, while we
see no signs of overfitting, even at the relatively low alignment
score cutoff of 5 used in this analysis. Peptides with higher ALC
(and fewer errors) yield higher alignment scores, as expected, but
to achieve optimal accuracy in the final consensus sequences, there
is an important trade-off to be made between selection of the highest-scoring
input reads and achieving optimal coverage. As the coverage plummets
with ALC cutoff scores &gt;95, it follows that a substantial tolerance
to mass coincidence errors is required to assemble the complete sequences
(given the limitations of the experimental input data) by including
lower ALC (&lt;95) peptides (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). Of note, SWA cannot align any peptides below ALC
55, while these may still be placed using MBA.</p>
    <fig id="fig3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Mass-based alignment
results. (A) Average normalized score (score/alignment
length) as a function of PEAKS ALC. Note that the missing points for
CutoffALC &lt; 55 for Smith–Waterman alignment is because no
peptides with these scores could be placed by this alignment algorithm.
(B) Result of running Stitch with the Herceptin and F59 sample data
with different read cutoff scores presented as accuracy, defined here
as identity against the true sequence, in a solid line, and coverage,
the fraction of positions covered by at least one peptide, drawn in
a dotted line. Note that the results were generated running Stitch
with a low cutoff score for template matching. (C) An excerpt of the
alignment of the highest scoring light chain variable gene from the
Stitch report for Herceptin using mass-based alignment and CutoffALC
85.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0003" id="gr3" position="float"/>
    </fig>
    <p>The accuracy of the final consensus
sequences of Herceptin and
F59 is plotted as a function of ALC cutoff in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B, illustrating that MBA outperforms SWA
across the sampled range. The accuracy increases from 0.95 (SWA) to
0.99 (MBA). While this may seem like a moderate increase at first,
it represents a better than 100-fold improvement in the probability
to determine the sequence of a 120 amino acid long variable domain
with zero mistakes (<italic>P</italic> = 0.002 for accuracy 0.95 vs <italic>P</italic> = 0.299 for accuracy 0.99). Of note, to achieve a probability
of <italic>P</italic> &gt; 0.99 to make zero mistakes in a sequence
of
this length, the accuracy needs to further improve to &gt;0.9999 (see <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>).</p>
    <fig id="fig4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Probability of the indicated number of errors in a sequence of
120 amino acids given the sequencing accuracy per amino acid.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0004" id="gr4" position="float"/>
    </fig>
    <p>In addition to the new MBA, Stitch is also updated
to read and
display fragmentation spectra in an interactive spectrum viewer (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A). This allows the user to manually inspect the underlying
data for an assigned sequence. Moreover, accessing the fragmentation
spectra in Stitch also allowed us to implement a new postprocessing
procedure to differentiate between leucine/isoleucine based on secondary
fragment ions that can be observed in some fragmentation modes, notably
electron transfer high energy collision dissociation data.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> These diagnostic satellite ions (known as <italic>w</italic>/<italic>d</italic>-ions) are formed by secondary fragmentation
of <italic>z-</italic> and <italic>a-</italic>ions, by transfer of
the free electron to the side chain, and breaking of a bond to the
first C atom in the side chain (Cβ). As the side chains are
different between isoleucine and leucine, the possible mass shifts
of the satellite ions are different, being 15 and 29 Da for isoleucine
(loss of C<sub>1</sub>H<sub>3</sub> and C<sub>2</sub>H<sub>5</sub>) and 43 Da for leucine (loss of C<sub>3</sub>H<sub>7</sub>). Stitch
gives the option to use these satellite ions to find the most likely
candidate for each I/L position. This improves the fraction of correctly
identified I/L positions from 0.81 (when defaulting to the germline
template sequence or to L in the case of newly introduced I/L mutations)
to 0.94 when using the satellite ions, as seen in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B.</p>
    <fig id="fig5" position="float">
      <label>Figure 5</label>
      <caption>
        <p>Satellite ion usage to
identify I/L. (A) Screenshot from the spectrum
viewer of a CDRH3 peptide of Herceptin. (B) The fraction of correct
I/L identifications using just the germline (previous version of Stitch)
or the new satellite ions; alignment identity is used as measure of
accuracy. (C) An example spectrum with satellite ions annotated as
Stitch would display it.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0005" id="gr5" position="float"/>
    </fig>
  </sec>
  <sec id="sec4">
    <title>Discussion</title>
    <p>These
recent updates to Stitch provide a better handle on mass
coincidence errors for <italic>de novo</italic> antibody sequencing
by LC-MS/MS. These improvements extend to any MS-based <italic>de
novo</italic> sequencing application beyond antibodies, and indeed,
Stitch can perform the same tasks on an arbitrary set of template
sequences.</p>
    <p>Implementation of the mass-based alignment shed light
on fundamental
requirements and limitations for MS-based <italic>de novo</italic> sequencing and set out some important goals for the near future.
To minimize peptide-level sequencing errors, it is crucially important
to analyze at a precision of at least 0.02 Da, achieve complete fragmentation,
and obtain secondary fragment ions to differentiate I/L. The latter
two points call for use of complementary fragmentation techniques
beyond CID. Currently, accuracies of 0.99 can be achieved on the consensus
sequence level, but to achieve a milestone 99% confidence in error-free
sequences, this needs to improve to &gt;0.9999 for the case of an
antibody
variable domain of 120 amino acids. Based on our own work, this requires
further improvement of I/L assignments, but even more so elimination
of deamidation errors (primarily N/D) from the sample processing workflows.
Moreover, the 0.99 accuracy is currently based on consensus sequences
from overlapping peptides, and as we expand applications to complex
polyclonal antibody mixtures, the depth of coverage will inevitably
suffer, again calling for improved fragmentation to minimize sequencing
errors at the peptide level. In addition to improved fragmentation,
recent improvements in retention time prediction may also be leveraged
in <italic>de novo</italic> peptide sequencing algorithms to improve
peptide-level sequence accuracy.<sup><xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup></p>
    <p>Stitch
is now compatible with a wide range of current de novo sequencing
algorithms, providing an improved strategy for sequence assembly with
mass-based alignment and the opportunity to browse spectrum-level
evidence for the determined sequence to aid in manual curation. It
is a versatile tool for MS-based antibody sequencing and beyond and
may provide a springboard to dive into the serum compartment of the
antibody repertoire with proteomics techniques.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes1">
    <title>Data Availability Statement</title>
    <p>The source code
of Stitch is available on GitHub: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/snijderlab/stitch">https://github.com/snijderlab/stitch</uri>. All Stitch HTML results related to this study are provided as Supporting
Data. The raw data of the monoclonal antibodies Herceptin and F59
are available under identifier PXD023419 and doi 10.6084/m9.figshare.13194005,
respectively.</p>
  </notes>
  <notes id="notes2" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00188?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00188</ext-link>.<list id="silist" list-type="simple"><list-item><p>Isobaric statistics;
mass-based benchmark, and xln disambiguation
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.4c00188/suppl_file/pr4c00188_si_001.zip">ZIP</ext-link>)</p></list-item><list-item><p>All
Stitch HTML results related to this study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.4c00188/suppl_file/pr4c00188_si_002.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_si_001.zip">
        <caption>
          <p>pr4c00188_si_001.zip</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_si_002.pdf">
        <caption>
          <p>pr4c00188_si_002.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d14e516-autogenerated">
    <p>The authors declare no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>The authors thank Bastiaan
de Graaf for the fruitful
discussions regarding the design of Stitch and the mass-based alignment
algorithm. We would also like to thank Lukas Käll for helpful
input and feedback on the manuscript. This research was funded by
the Dutch Research Council NWO Gravitation 2013 BOO, Institute for
Chemical Immunology (ICI; 024.002.009), and the European Research
Council Executive Agency HORIZON ERC-2022-STG (FLAVIR; 101077640).</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Casadevall</surname><given-names>A.</given-names></name>; <name><surname>Pirofski</surname><given-names>L.</given-names></name><article-title>A New Synthesis for
Antibody-Mediated Immunity</article-title>. <source>Nat. Immunol</source><year>2012</year>, <volume>13</volume> (<issue>1</issue>), <fpage>21</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2184</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Davies</surname><given-names>D. R.</given-names></name>; <name><surname>Metzger</surname><given-names>H.</given-names></name><article-title>Structural Basis of
Antibody Function</article-title>. <source>Annu. Rev. Immunol.</source><year>1983</year>, <volume>1</volume> (<issue>1</issue>), <fpage>87</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.iy.01.040183.000511</pub-id>.<pub-id pub-id-type="pmid">6399980</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Lleo</surname><given-names>A.</given-names></name>; <name><surname>Invernizzi</surname><given-names>P.</given-names></name>; <name><surname>Gao</surname><given-names>B.</given-names></name>; <name><surname>Podda</surname><given-names>M.</given-names></name>; <name><surname>Gershwin</surname><given-names>M. E.</given-names></name><article-title>Definition
of Human Autoimmunity — Autoantibodies versus Autoimmune Disease</article-title>. <source>Autoimmun Rev.</source><year>2010</year>, <volume>9</volume> (<issue>5</issue>), <fpage>A259</fpage>–<lpage>A266</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2009.12.002</pub-id>.<pub-id pub-id-type="pmid">19963079</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Naparstek</surname><given-names>Y.</given-names></name>; <name><surname>Plotz</surname><given-names>P. H.</given-names></name><article-title>The Role of Autoantibodies
in Autoimmune Disease</article-title>. <source>Annu. Rev. Immunol.</source><year>1993</year>, <volume>11</volume> (<issue>1</issue>), <fpage>79</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.iy.11.040193.000455</pub-id>.<pub-id pub-id-type="pmid">8476578</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Avram</surname><given-names>O.</given-names></name>; <name><surname>Kigel</surname><given-names>A.</given-names></name>; <name><surname>Vaisman-Mentesh</surname><given-names>A.</given-names></name>; <name><surname>Kligsberg</surname><given-names>S.</given-names></name>; <name><surname>Rosenstein</surname><given-names>S.</given-names></name>; <name><surname>Dror</surname><given-names>Y.</given-names></name>; <name><surname>Pupko</surname><given-names>T.</given-names></name>; <name><surname>Wine</surname><given-names>Y.</given-names></name><article-title>PASA: Proteomic
Analysis of Serum Antibodies Web Server</article-title>. <source>PLoS
Comput. Biol.</source><year>2021</year>, <volume>17</volume> (<issue>1</issue>), <elocation-id>e1008607</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008607</pub-id>.<pub-id pub-id-type="pmid">33493161</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Lavinder</surname><given-names>J. J.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name><article-title>Next-Generation
Sequencing and Protein Mass Spectrometry for the Comprehensive Analysis
of Human Cellular and Serum Antibody Repertoires</article-title>. <source>Curr. Opin Chem. Biol.</source><year>2015</year>, <volume>24</volume>, <fpage>112</fpage>–<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2014.11.007</pub-id>.<pub-id pub-id-type="pmid">25461729</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Chromikova</surname><given-names>V.</given-names></name>; <name><surname>Joyce</surname><given-names>M. G.</given-names></name>; <name><surname>Vollmers</surname><given-names>C.</given-names></name>; <name><surname>Leung</surname><given-names>K.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>DeKosky</surname><given-names>B. J.</given-names></name>; <name><surname>Lee</surname><given-names>C.-H.</given-names></name>; <name><surname>Lavinder</surname><given-names>J. J.</given-names></name>; <name><surname>Murrin</surname><given-names>E. M.</given-names></name>; <name><surname>Chrysostomou</surname><given-names>C.</given-names></name>; <name><surname>Hoi</surname><given-names>K. H.</given-names></name>; <name><surname>Tsybovsky</surname><given-names>Y.</given-names></name>; <name><surname>Thomas</surname><given-names>P. V.</given-names></name>; <name><surname>Druz</surname><given-names>A.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Kong</surname><given-names>W.-P.</given-names></name>; <name><surname>Park</surname><given-names>D.</given-names></name>; <name><surname>Popova</surname><given-names>L. I.</given-names></name>; <name><surname>Dekker</surname><given-names>C. L.</given-names></name>; <name><surname>Davis</surname><given-names>M. M.</given-names></name>; <name><surname>Carter</surname><given-names>C. E.</given-names></name>; <name><surname>Ross</surname><given-names>T. M.</given-names></name>; <name><surname>Ellington</surname><given-names>A. D.</given-names></name>; <name><surname>Wilson</surname><given-names>P. C.</given-names></name>; <name><surname>Marcotte</surname><given-names>E. M.</given-names></name>; <name><surname>Mascola</surname><given-names>J. R.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name>; <name><surname>Krammer</surname><given-names>F.</given-names></name>; <name><surname>Quake</surname><given-names>S. R.</given-names></name>; <name><surname>Kwong</surname><given-names>P. D.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name><article-title>Molecular-Level
Analysis of the Serum Antibody Repertoire in Young Adults before and
after Seasonal Influenza Vaccination</article-title>. <source>Nat. Med.</source><year>2016</year>, <volume>22</volume> (<issue>12</issue>), <fpage>1456</fpage>–<lpage>1464</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4224</pub-id>.<pub-id pub-id-type="pmid">27820605</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Paparoditis</surname><given-names>P.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>Frühwirth</surname><given-names>A.</given-names></name>; <name><surname>McDaniel</surname><given-names>J. R.</given-names></name>; <name><surname>Jung</surname><given-names>J.</given-names></name>; <name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Hussein</surname><given-names>D. A.</given-names></name>; <name><surname>Tanno</surname><given-names>Y.</given-names></name>; <name><surname>Pappas</surname><given-names>L.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name>; <name><surname>Corti</surname><given-names>D.</given-names></name>; <name><surname>Lanzavecchia</surname><given-names>A.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name><article-title>Persistent Antibody Clonotypes Dominate
the Serum Response to Influenza over Multiple Years and Repeated Vaccinations</article-title>. <source>Cell Host Microb.</source><year>2019</year>, <volume>25</volume> (<issue>3</issue>), <fpage>367</fpage>–<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2019.01.010</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Lindesmith</surname><given-names>L. C.</given-names></name>; <name><surname>McDaniel</surname><given-names>J. R.</given-names></name>; <name><surname>Changela</surname><given-names>A.</given-names></name>; <name><surname>Verardi</surname><given-names>R.</given-names></name>; <name><surname>Kerr</surname><given-names>S. A.</given-names></name>; <name><surname>Costantini</surname><given-names>V.</given-names></name>; <name><surname>Brewer-Jensen</surname><given-names>P. D.</given-names></name>; <name><surname>Mallory</surname><given-names>M. L.</given-names></name>; <name><surname>Voss</surname><given-names>W. N.</given-names></name>; <name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Blazeck</surname><given-names>J. J.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name>; <name><surname>Vinje</surname><given-names>J.</given-names></name>; <name><surname>Kwong</surname><given-names>P. D.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name>; <name><surname>Baric</surname><given-names>R. S.</given-names></name><article-title>Sera Antibody Repertoire
Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing
Responses after Human Norovirus Vaccination</article-title>. <source>Immunity</source><year>2019</year>, <volume>50</volume> (<issue>6</issue>), <fpage>1530</fpage>–<lpage>1541</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2019.05.007</pub-id>.<pub-id pub-id-type="pmid">31216462</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>Wine</surname><given-names>Y.</given-names></name>; <name><surname>Lavinder</surname><given-names>J. J.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name>; <name><surname>Marcotte</surname><given-names>E. M.</given-names></name><article-title>Proteomic Identification of Monoclonal Antibodies from
Serum</article-title>. <source>Anal. Chem.</source><year>2014</year>, <volume>86</volume> (<issue>10</issue>), <fpage>4758</fpage>–<lpage>4766</lpage>. <pub-id pub-id-type="doi">10.1021/ac4037679</pub-id>.<pub-id pub-id-type="pmid">24684310</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Ellebrecht</surname><given-names>C. T.</given-names></name>; <name><surname>Mukherjee</surname><given-names>E. M.</given-names></name>; <name><surname>Zheng</surname><given-names>Q.</given-names></name>; <name><surname>Choi</surname><given-names>E. J.</given-names></name>; <name><surname>Reddy</surname><given-names>S. G.</given-names></name>; <name><surname>Mao</surname><given-names>X.</given-names></name>; <name><surname>Payne</surname><given-names>A. S.</given-names></name><article-title>Autoreactive IgG and IgA B Cells Evolve through Distinct
Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris</article-title>. <source>Cell Rep</source><year>2018</year>, <volume>24</volume> (<issue>9</issue>), <fpage>2370</fpage>–<lpage>2380</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.093</pub-id>.<pub-id pub-id-type="pmid">30157430</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Fridy</surname><given-names>P. C.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Keegan</surname><given-names>S.</given-names></name>; <name><surname>Thompson</surname><given-names>M. K.</given-names></name>; <name><surname>Nudelman</surname><given-names>I.</given-names></name>; <name><surname>Scheid</surname><given-names>J. F.</given-names></name>; <name><surname>Oeffinger</surname><given-names>M.</given-names></name>; <name><surname>Nussenzweig</surname><given-names>M. C.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Chait</surname><given-names>B. T.</given-names></name>; <name><surname>Rout</surname><given-names>M. P.</given-names></name><article-title>A Robust
Pipeline for Rapid Production
of Versatile Nanobody Repertoires</article-title>. <source>Nat. Methods</source><year>2014</year>, <volume>11</volume> (<issue>12</issue>), <fpage>1253</fpage>–<lpage>1260</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3170</pub-id>.<pub-id pub-id-type="pmid">25362362</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Bondt</surname><given-names>A.</given-names></name>; <name><surname>Hoek</surname><given-names>M.</given-names></name>; <name><surname>Dingess</surname><given-names>K.</given-names></name>; <name><surname>Tamara</surname><given-names>S.</given-names></name>; <name><surname>de Graaf</surname><given-names>B.</given-names></name>; <name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>den Boer</surname><given-names>M. A.</given-names></name>; <name><surname>Damen</surname><given-names>M.</given-names></name>; <name><surname>Zwart</surname><given-names>C.</given-names></name>; <name><surname>Barendregt</surname><given-names>A.</given-names></name>; <name><surname>van Rijswijck</surname><given-names>D. M. H.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Grobben</surname><given-names>M.</given-names></name>; <name><surname>Tejjani</surname><given-names>K.</given-names></name>; <name><surname>van Rijswijk</surname><given-names>J.</given-names></name>; <name><surname>Völlmy</surname><given-names>F.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name>; <name><surname>Fortini</surname><given-names>F.</given-names></name>; <name><surname>Papi</surname><given-names>A.</given-names></name>; <name><surname>Volta</surname><given-names>C. A.</given-names></name>; <name><surname>Campo</surname><given-names>G.</given-names></name>; <name><surname>Contoli</surname><given-names>M.</given-names></name>; <name><surname>van Gils</surname><given-names>M. J.</given-names></name>; <name><surname>Spadaro</surname><given-names>S.</given-names></name>; <name><surname>Rizzo</surname><given-names>P.</given-names></name>; <name><surname>Heck</surname><given-names>A. J. R.</given-names></name><article-title>Into
the Dark Serum Proteome: Personalized
Features of IgG1 and IgA1 Repertoires in Severe COVID-19 Patients</article-title>. <source>Molecular &amp; Cellular Proteomics</source><year>2024</year>, <volume>23</volume> (<issue>1</issue>), <elocation-id>100690</elocation-id><pub-id pub-id-type="doi">10.1016/j.mcpro.2023.100690</pub-id>.<pub-id pub-id-type="pmid">38065436</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>den Boer</surname><given-names>M. A.</given-names></name>; <name><surname>Tamara</surname><given-names>S.</given-names></name>; <name><surname>Mokiem</surname><given-names>N. J.</given-names></name>; <name><surname>van der
Lans</surname><given-names>S. P. A.</given-names></name>; <name><surname>Bondt</surname><given-names>A.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Haas</surname><given-names>P.-J.</given-names></name>; <name><surname>Minnema</surname><given-names>M. C.</given-names></name>; <name><surname>Rooijakkers</surname><given-names>S. H. M.</given-names></name>; <name><surname>van Zuilen</surname><given-names>A. D.</given-names></name>; <name><surname>Heck</surname><given-names>A. J. R.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Direct Mass Spectrometry-Based Detection
and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance
from Patient Serum: A Case Study</article-title>. <source>J. Proteome
Res.</source><year>2023</year>, <volume>22</volume> (<issue>9</issue>), <fpage>3022</fpage>–<lpage>3028</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.3c00330</pub-id>.<pub-id pub-id-type="pmid">37499263</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Bondt</surname><given-names>A.</given-names></name>; <name><surname>Hoek</surname><given-names>M.</given-names></name>; <name><surname>Tamara</surname><given-names>S.</given-names></name>; <name><surname>de Graaf</surname><given-names>B.</given-names></name>; <name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>van Rijswijck</surname><given-names>D. M. H.</given-names></name>; <name><surname>den Boer</surname><given-names>M. A.</given-names></name>; <name><surname>Greisch</surname><given-names>J. F.</given-names></name>; <name><surname>Varkila</surname><given-names>M. R. J.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name>; <name><surname>Cremer</surname><given-names>O. L.</given-names></name>; <name><surname>Bonten</surname><given-names>M. J. M.</given-names></name>; <name><surname>Heck</surname><given-names>A. J. R.</given-names></name><article-title>Human Plasma
IgG1 Repertoires Are Simple, Unique, and
Dynamic</article-title>. <source>Cell Syst</source><year>2021</year>, <volume>12</volume> (<issue>12</issue>), <fpage>1131</fpage>–<lpage>1143</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2021.08.008</pub-id>.<pub-id pub-id-type="pmid">34613904</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Tran</surname><given-names>N. H.</given-names></name>; <name><surname>Rahman</surname><given-names>M. Z.</given-names></name>; <name><surname>He</surname><given-names>L.</given-names></name>; <name><surname>Xin</surname><given-names>L.</given-names></name>; <name><surname>Shan</surname><given-names>B.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name><article-title>Complete De Novo Assembly of Monoclonal
Antibody Sequences</article-title>. <source>Sci. Rep</source><year>2016</year>, <volume>6</volume> (<issue>1</issue>), <fpage>31730</fpage><pub-id pub-id-type="doi">10.1038/srep31730</pub-id>.<pub-id pub-id-type="pmid">27562653</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Sousa</surname><given-names>E.</given-names></name>; <name><surname>Olland</surname><given-names>S.</given-names></name>; <name><surname>Shih</surname><given-names>H. H.</given-names></name>; <name><surname>Marquette</surname><given-names>K.</given-names></name>; <name><surname>Martone</surname><given-names>R.</given-names></name>; <name><surname>Lu</surname><given-names>Z.</given-names></name>; <name><surname>Paulsen</surname><given-names>J.</given-names></name>; <name><surname>Gill</surname><given-names>D.</given-names></name>; <name><surname>He</surname><given-names>T.</given-names></name><article-title>Primary Sequence Determination of
a Monoclonal Antibody against α-Synuclein
Using a Novel Mass Spectrometry-Based Approach</article-title>. <source>Int. J. Mass Spectrom.</source><year>2012</year>, <volume>312</volume>, <fpage>61</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijms.2011.05.005</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Sen</surname><given-names>K. I.</given-names></name>; <name><surname>Tang</surname><given-names>W. H.</given-names></name>; <name><surname>Nayak</surname><given-names>S.</given-names></name>; <name><surname>Kil</surname><given-names>Y. J.</given-names></name>; <name><surname>Bern</surname><given-names>M.</given-names></name>; <name><surname>Ozoglu</surname><given-names>B.</given-names></name>; <name><surname>Ueberheide</surname><given-names>B.</given-names></name>; <name><surname>Davis</surname><given-names>D.</given-names></name>; <name><surname>Becker</surname><given-names>C.</given-names></name><article-title>Automated
Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery</article-title>. <source>J. Am. Soc. Mass Spectrom.</source><year>2017</year>, <volume>28</volume> (<issue>5</issue>), <fpage>803</fpage>–<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1007/s13361-016-1580-0</pub-id>.<pub-id pub-id-type="pmid">28105549</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Rickert</surname><given-names>K. W.</given-names></name>; <name><surname>Grinberg</surname><given-names>L.</given-names></name>; <name><surname>Woods</surname><given-names>R. M.</given-names></name>; <name><surname>Wilson</surname><given-names>S.</given-names></name>; <name><surname>Bowen</surname><given-names>M. A.</given-names></name>; <name><surname>Baca</surname><given-names>M.</given-names></name><article-title>Combining Phage Display
with de Novo Protein Sequencing for Reverse
Engineering of Monoclonal Antibodies</article-title>. <source>MAbs</source><year>2016</year>, <volume>8</volume> (<issue>3</issue>), <fpage>501</fpage>–<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1080/19420862.2016.1145865</pub-id>.<pub-id pub-id-type="pmid">26852694</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Savidor</surname><given-names>A.</given-names></name>; <name><surname>Barzilay</surname><given-names>R.</given-names></name>; <name><surname>Elinger</surname><given-names>D.</given-names></name>; <name><surname>Yarden</surname><given-names>Y.</given-names></name>; <name><surname>Lindzen</surname><given-names>M.</given-names></name>; <name><surname>Gabashvili</surname><given-names>A.</given-names></name>; <name><surname>Adiv Tal</surname><given-names>O.</given-names></name>; <name><surname>Levin</surname><given-names>Y.</given-names></name><article-title>Database-Independent
Protein Sequencing (DiPS) Enables Full-Length de Novo Protein and
Antibody Sequence Determination</article-title>. <source>Molecular &amp;
Cellular Proteomics</source><year>2017</year>, <volume>16</volume> (<issue>6</issue>), <fpage>1151</fpage>–<lpage>1161</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.O116.065417</pub-id>.<pub-id pub-id-type="pmid">28348172</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Pronker</surname><given-names>M. F.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Mass Spectrometry-Based <italic>De
Novo</italic> Sequencing of Monoclonal Antibodies Using Multiple Proteases
and a Dual Fragmentation Scheme</article-title>. <source>J. Proteome
Res.</source><year>2021</year>, <volume>20</volume> (<issue>7</issue>), <fpage>3559</fpage>–<lpage>3566</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.1c00169</pub-id>.<pub-id pub-id-type="pmid">34121409</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Guthals</surname><given-names>A.</given-names></name>; <name><surname>Gan</surname><given-names>Y.</given-names></name>; <name><surname>Murray</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Stinson</surname><given-names>J.</given-names></name>; <name><surname>Nakamura</surname><given-names>G.</given-names></name>; <name><surname>Lill</surname><given-names>J. R.</given-names></name>; <name><surname>Sandoval</surname><given-names>W.</given-names></name>; <name><surname>Bandeira</surname><given-names>N.</given-names></name><article-title>De Novo MS/MS Sequencing
of Native Human Antibodies</article-title>. <source>J. Proteome Res.</source><year>2017</year>, <volume>16</volume> (<issue>1</issue>), <fpage>45</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00608</pub-id>.<pub-id pub-id-type="pmid">27779884</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Cheung</surname><given-names>W. C.</given-names></name>; <name><surname>Beausoleil</surname><given-names>S. A.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Sato</surname><given-names>S.</given-names></name>; <name><surname>Schieferl</surname><given-names>S. M.</given-names></name>; <name><surname>Wieler</surname><given-names>J. S.</given-names></name>; <name><surname>Beaudet</surname><given-names>J. G.</given-names></name>; <name><surname>Ramenani</surname><given-names>R. K.</given-names></name>; <name><surname>Popova</surname><given-names>L.</given-names></name>; <name><surname>Comb</surname><given-names>M. J.</given-names></name>; <name><surname>Rush</surname><given-names>J.</given-names></name>; <name><surname>Polakiewicz</surname><given-names>R. D.</given-names></name><article-title>A Proteomics
Approach for the Identification and Cloning of Monoclonal Antibodies
from Serum</article-title>. <source>Nat. Biotechnol.</source><year>2012</year>, <volume>30</volume> (<issue>5</issue>), <fpage>447</fpage>–<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2167</pub-id>.<pub-id pub-id-type="pmid">22446692</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Castellana</surname><given-names>N. E.</given-names></name>; <name><surname>McCutcheon</surname><given-names>K.</given-names></name>; <name><surname>Pham</surname><given-names>V. C.</given-names></name>; <name><surname>Harden</surname><given-names>K.</given-names></name>; <name><surname>Nguyen</surname><given-names>A.</given-names></name>; <name><surname>Young</surname><given-names>J.</given-names></name>; <name><surname>Adams</surname><given-names>C.</given-names></name>; <name><surname>Schroeder</surname><given-names>K.</given-names></name>; <name><surname>Arnott</surname><given-names>D.</given-names></name>; <name><surname>Bafna</surname><given-names>V.</given-names></name>; <name><surname>Grogan</surname><given-names>J. L.</given-names></name>; <name><surname>Lill</surname><given-names>J. R.</given-names></name><article-title>Resurrection
of a Clinical Antibody: Template Proteogenomic de Novo Proteomic Sequencing
and Reverse Engineering of an Anti-lymphotoxin-α Antibody</article-title>. <source>Proteomics</source><year>2011</year>, <volume>11</volume> (<issue>3</issue>), <fpage>395</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1002/pmic.201000487</pub-id>.<pub-id pub-id-type="pmid">21268269</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Bandeira</surname><given-names>N.</given-names></name>; <name><surname>Pham</surname><given-names>V.</given-names></name>; <name><surname>Pevzner</surname><given-names>P.</given-names></name>; <name><surname>Arnott</surname><given-names>D.</given-names></name>; <name><surname>Lill</surname><given-names>J. R.</given-names></name><article-title>Automated
de Novo Protein Sequencing of Monoclonal Antibodies</article-title>. <source>Nat. Biotechnol.</source><year>2008</year>, <volume>26</volume> (<issue>12</issue>), <fpage>1336</fpage>–<lpage>1338</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1208-1336</pub-id>.<pub-id pub-id-type="pmid">19060866</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Giesbers</surname><given-names>K. C.</given-names></name>; <name><surname>Šiborová</surname><given-names>M.</given-names></name>; <name><surname>Beugelink</surname><given-names>J. W.</given-names></name>; <name><surname>Pronker</surname><given-names>M. F.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Hilkens</surname><given-names>J.</given-names></name>; <name><surname>Janssen</surname><given-names>B. J.</given-names></name>; <name><surname>Strijbis</surname><given-names>K.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Reverse-Engineering
the Anti-MUC1
Antibody 139H2 by Mass Spectrometry–Based de Novo Sequencing</article-title>. <source>Life Sci. Alliance</source><year>2024</year>, <volume>7</volume> (<issue>6</issue>), <elocation-id>e202302366</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.202302366</pub-id>.<pub-id pub-id-type="pmid">38508723</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Template-Based
Assembly of Proteomic
Short Reads For <italic>De Novo</italic> Antibody Sequencing and Repertoire
Profiling</article-title>. <source>Anal. Chem.</source><year>2022</year>, <volume>94</volume> (<issue>29</issue>), <fpage>10391</fpage>–<lpage>10399</lpage>. <pub-id pub-id-type="doi">10.1021/acs.analchem.2c01300</pub-id>.<pub-id pub-id-type="pmid">35834437</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Giesbers</surname><given-names>K. C. A. P.</given-names></name>; <name><surname>Šiborová</surname><given-names>M.</given-names></name>; <name><surname>Beugelink</surname><given-names>J. W.</given-names></name>; <name><surname>Pronker</surname><given-names>M. F.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Hilkens</surname><given-names>J.</given-names></name>; <name><surname>Janssen</surname><given-names>B. J. C.</given-names></name>; <name><surname>Strijbis</surname><given-names>K.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Reverse Engineering the Anti-MUC1
Hybridoma Antibody 139H2 by Mass Spectrometry-Based de Novo Sequencing</article-title>. <source>bioRxiv</source><year>2023</year>, <pub-id pub-id-type="doi">10.1101/2023.07.05.547778</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Ivanov</surname><given-names>D. G.</given-names></name>; <name><surname>Ivetic</surname><given-names>N.</given-names></name>; <name><surname>Du</surname><given-names>Y.</given-names></name>; <name><surname>Nguyen</surname><given-names>S. N.</given-names></name>; <name><surname>Le</surname><given-names>S. H.</given-names></name>; <name><surname>Favre</surname><given-names>D.</given-names></name>; <name><surname>Nazy</surname><given-names>I.</given-names></name>; <name><surname>Kaltashov</surname><given-names>I. A.</given-names></name><article-title>Reverse
Engineering of a Pathogenic Antibody Reveals the Molecular Mechanism
of Vaccine-Induced Immune Thrombotic Thrombocytopenia</article-title>. <source>J. Am. Chem. Soc.</source><year>2023</year>, <volume>145</volume> (<issue>46</issue>), <fpage>25203</fpage>–<lpage>25213</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.3c07846</pub-id>.<pub-id pub-id-type="pmid">37949820</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Guthals</surname><given-names>A.</given-names></name>; <name><surname>Clauser</surname><given-names>K. R.</given-names></name>; <name><surname>Bandeira</surname><given-names>N.</given-names></name><article-title>Shotgun Protein
Sequencing with Meta-Contig
Assembly</article-title>. <source>Molecular &amp; Cellular Proteomics</source><year>2012</year>, <volume>11</volume> (<issue>10</issue>), <fpage>1084</fpage>–<lpage>1096</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M111.015768</pub-id>.<pub-id pub-id-type="pmid">22798278</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="undeclared" id="cit31"><person-group person-group-type="allauthors"><name><surname>Yilmaz</surname><given-names>M.</given-names></name>; <name><surname>Fondrie</surname><given-names>W. E.</given-names></name>; <name><surname>Bittremieux</surname><given-names>W.</given-names></name>; <name><surname>Oh</surname><given-names>S.</given-names></name>; <name><surname>Noble</surname><given-names>W. S.</given-names></name></person-group><source>De Novo Mass Spectrometry Peptide
Sequencing with a Transformer Model</source>. <publisher-name>PMLR
June</publisher-name><volume>28</volume>, <year>2022</year>; pp <fpage>25514</fpage>–<lpage>25522</lpage>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://proceedings.mlr.press/v162/yilmaz22a.html">https://proceedings.mlr.press/v162/yilmaz22a.html</uri> (accessed 2024–01–30).</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Yilmaz</surname><given-names>M.</given-names></name>; <name><surname>Fondrie</surname><given-names>W. E.</given-names></name>; <name><surname>Bittremieux</surname><given-names>W.</given-names></name>; <name><surname>Nelson</surname><given-names>R.</given-names></name>; <name><surname>Ananth</surname><given-names>V.</given-names></name>; <name><surname>Oh</surname><given-names>S.</given-names></name>; <name><surname>Noble</surname><given-names>W. S.</given-names></name>; <name><surname>Allen</surname><given-names>P. G.</given-names></name><article-title>Sequence-to-Sequence Translation
from Mass Spectra to Peptides with a Transformer Model</article-title>. <source>bioRxiv</source><year>2023</year>, <pub-id pub-id-type="doi">10.1101/2023.01.03.522621</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Gutenbrunner</surname><given-names>P.</given-names></name>; <name><surname>Kyriakidou</surname><given-names>P.</given-names></name>; <name><surname>Welker</surname><given-names>F.</given-names></name>; <name><surname>Cox</surname><given-names>J.</given-names></name><article-title>Spectrum Graph-Based
de-Novo Sequencing Algorithm MaxNovo Achieves High Peptide Identification
Rates in Collisional Dissociation MS/MS Spectra</article-title>. <source>bioRxiv</source><year>2021</year>, <pub-id pub-id-type="doi">10.1101/2021.09.04.458985</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Ma</surname><given-names>B.</given-names></name><article-title>Novor: Real-Time
Peptide de Novo Sequencing Software</article-title>. <source>J. Am.
Soc. Mass Spectrom.</source><year>2015</year>, <volume>26</volume> (<issue>11</issue>), <fpage>1885</fpage>–<lpage>1894</lpage>. <pub-id pub-id-type="doi">10.1007/s13361-015-1204-0</pub-id>.<pub-id pub-id-type="pmid">26122521</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Tran</surname><given-names>N. H.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Xin</surname><given-names>L.</given-names></name>; <name><surname>Shan</surname><given-names>B.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name><article-title>De Novo Peptide
Sequencing by Deep Learning</article-title>. <source>Proc. Natl. Acad.
Sci. U. S. A.</source><year>2017</year>, <volume>114</volume> (<issue>31</issue>), <fpage>8247</fpage>–<lpage>8252</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1705691114</pub-id>.<pub-id pub-id-type="pmid">28720701</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Chi</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>He</surname><given-names>K.</given-names></name>; <name><surname>Wu</surname><given-names>L.</given-names></name>; <name><surname>Yang</surname><given-names>B.</given-names></name>; <name><surname>Sun</surname><given-names>R.-X.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Zeng</surname><given-names>W.-F.</given-names></name>; <name><surname>Song</surname><given-names>C.-Q.</given-names></name>; <name><surname>He</surname><given-names>S.-M.</given-names></name>; <name><surname>Dong</surname><given-names>M.-Q.</given-names></name><article-title>pNovo+: De Novo
Peptide Sequencing
Using Complementary HCD and ETD Tandem Mass Spectra</article-title>. <source>J. Proteome Res.</source><year>2013</year>, <volume>12</volume> (<issue>2</issue>), <fpage>615</fpage>–<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1021/pr3006843</pub-id>.<pub-id pub-id-type="pmid">23272783</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Chi</surname><given-names>H.</given-names></name>; <name><surname>Sun</surname><given-names>R.-X.</given-names></name>; <name><surname>Yang</surname><given-names>B.</given-names></name>; <name><surname>Song</surname><given-names>C.-Q.</given-names></name>; <name><surname>Wang</surname><given-names>L.-H.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Fu</surname><given-names>Y.</given-names></name>; <name><surname>Yuan</surname><given-names>Z.-F.</given-names></name>; <name><surname>Wang</surname><given-names>H.-P.</given-names></name>; <name><surname>He</surname><given-names>S.-M.</given-names></name>; <name><surname>Dong</surname><given-names>M.-Q.</given-names></name><article-title>pNovo: <italic>De Novo</italic> Peptide Sequencing
and Identification Using HCD Spectra</article-title>. <source>J. Proteome
Res.</source><year>2010</year>, <volume>9</volume> (<issue>5</issue>), <fpage>2713</fpage>–<lpage>2724</lpage>. <pub-id pub-id-type="doi">10.1021/pr100182k</pub-id>.<pub-id pub-id-type="pmid">20329752</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Chi</surname><given-names>H.</given-names></name>; <name><surname>Zhou</surname><given-names>W.-J.</given-names></name>; <name><surname>Zeng</surname><given-names>W.-F.</given-names></name>; <name><surname>He</surname><given-names>K.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Sun</surname><given-names>R.-X.</given-names></name>; <name><surname>He</surname><given-names>S.-M.</given-names></name><article-title>Open-pNovo: De Novo Peptide Sequencing
with Thousands of Protein Modifications</article-title>. <source>J.
Proteome Res.</source><year>2017</year>, <volume>16</volume> (<issue>2</issue>), <fpage>645</fpage>–<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00716</pub-id>.<pub-id pub-id-type="pmid">28019094</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="journal" id="cit39"><name><surname>Needleman</surname><given-names>S. B.</given-names></name>; <name><surname>Wunsch</surname><given-names>C. D.</given-names></name><article-title>A General Method Applicable to the
Search for Similarities
in the Amino Acid Sequence of Two Proteins</article-title>. <source>J. Mol. Biol.</source><year>1970</year>, <volume>48</volume> (<issue>3</issue>), <fpage>443</fpage>–<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1016/0022-2836(70)90057-4</pub-id>.<pub-id pub-id-type="pmid">5420325</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Smith</surname><given-names>T. F.</given-names></name>; <name><surname>Waterman</surname><given-names>M. S.</given-names></name><article-title>Comparison of Biosequences</article-title>. <source>Adv.
Appl. Math</source><year>1981</year>, <volume>2</volume> (<issue>4</issue>), <fpage>482</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1016/0196-8858(81)90046-4</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Henikoff</surname><given-names>S.</given-names></name>; <name><surname>Henikoff</surname><given-names>J. G.</given-names></name><article-title>Amino Acid Substitution Matrices
from Protein Blocks</article-title>. <source>Proc. Natl. Acad. Sci.
U. S. A.</source><year>1992</year>, <volume>89</volume> (<issue>22</issue>), <fpage>10915</fpage>–<lpage>10919</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.89.22.10915</pub-id>.<pub-id pub-id-type="pmid">1438297</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="journal" id="cit42"><name><surname>Johnson</surname><given-names>R. S.</given-names></name>; <name><surname>Martin</surname><given-names>S. A.</given-names></name>; <name><surname>Biemann</surname><given-names>K.</given-names></name><article-title>Collision-Induced Fragmentation
of
(M + H)+ Ions of Peptides. Side Chain Specific Sequence Ions</article-title>. <source>Int. J. Mass Spectrom Ion Process</source><year>1988</year>, <volume>86</volume>, <fpage>137</fpage>–<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/0168-1176(88)80060-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Bouwmeester</surname><given-names>R.</given-names></name>; <name><surname>Gabriels</surname><given-names>R.</given-names></name>; <name><surname>Hulstaert</surname><given-names>N.</given-names></name>; <name><surname>Martens</surname><given-names>L.</given-names></name>; <name><surname>Degroeve</surname><given-names>S.</given-names></name><article-title>DeepLC Can
Predict Retention Times for Peptides That Carry As-yet Unseen Modifications</article-title>. <source>Nat. Methods</source><year>2021</year>, <volume>18</volume> (<issue>11</issue>), <fpage>1363</fpage>–<lpage>1369</lpage>. <pub-id pub-id-type="doi">10.1038/s41592-021-01301-5</pub-id>.<pub-id pub-id-type="pmid">34711972</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="journal" id="cit44"><name><surname>Sinitcyn</surname><given-names>P.</given-names></name>; <name><surname>Hamzeiy</surname><given-names>H.</given-names></name>; <name><surname>Salinas
Soto</surname><given-names>F.</given-names></name>; <name><surname>Itzhak</surname><given-names>D.</given-names></name>; <name><surname>McCarthy</surname><given-names>F.</given-names></name>; <name><surname>Wichmann</surname><given-names>C.</given-names></name>; <name><surname>Steger</surname><given-names>M.</given-names></name>; <name><surname>Ohmayer</surname><given-names>U.</given-names></name>; <name><surname>Distler</surname><given-names>U.</given-names></name>; <name><surname>Kaspar-Schoenefeld</surname><given-names>S.</given-names></name>; <name><surname>Prianichnikov</surname><given-names>N.</given-names></name>; <name><surname>Yılmaz</surname><given-names>Ş.</given-names></name>; <name><surname>Rudolph</surname><given-names>J. D.</given-names></name>; <name><surname>Tenzer</surname><given-names>S.</given-names></name>; <name><surname>Perez-Riverol</surname><given-names>Y.</given-names></name>; <name><surname>Nagaraj</surname><given-names>N.</given-names></name>; <name><surname>Humphrey</surname><given-names>S. J.</given-names></name>; <name><surname>Cox</surname><given-names>J.</given-names></name><article-title>MaxDIA Enables
Library-Based
and Library-Free Data-Independent Acquisition Proteomics</article-title>. <source>Nat. Biotechnol.</source><year>2021</year>, <volume>39</volume> (<issue>12</issue>), <fpage>1563</fpage>–<lpage>1573</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-021-00968-7</pub-id>.<pub-id pub-id-type="pmid">34239088</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Proteome Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Proteome Res</journal-id>
    <journal-id journal-id-type="publisher-id">pr</journal-id>
    <journal-id journal-id-type="coden">jprobs</journal-id>
    <journal-title-group>
      <journal-title>Journal of Proteome Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1535-3893</issn>
    <issn pub-type="epub">1535-3907</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11301774</article-id>
    <article-id pub-id-type="pmid">38932690</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jproteome.4c00188</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>A Handle on Mass
Coincidence Errors in <italic>De
Novo</italic> Sequencing of Antibodies by Bottom-up Proteomics</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0594-0993</contrib-id>
        <name>
          <surname>Schulte</surname>
          <given-names>Douwe</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9310-8226</contrib-id>
        <name>
          <surname>Snijder</surname>
          <given-names>Joost</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
      </contrib>
      <aff id="aff1">Biomolecular Mass Spectrometry
and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht
Institute of Pharmaceutical Sciences, <institution>Utrecht
University</institution>, Padualaan 8, Utrecht 3584
CH, <country>The Netherlands</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>j.snijder@uu.nl</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>27</day>
      <month>06</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>02</day>
      <month>08</month>
      <year>2024</year>
    </pub-date>
    <volume>23</volume>
    <issue>8</issue>
    <fpage>3552</fpage>
    <lpage>3559</lpage>
    <history>
      <date date-type="received">
        <day>11</day>
        <month>03</month>
        <year>2024</year>
      </date>
      <date date-type="accepted">
        <day>20</day>
        <month>06</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>29</day>
        <month>05</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2024 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2024</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0006" id="ab-tgr1"/>
      </p>
      <p>Antibody sequences
can be determined at 99% accuracy directly from
the polypeptide product by using bottom-up proteomics techniques.
Sequencing accuracy at the peptide level is limited by the isobaric
residues leucine and isoleucine, incomplete fragmentation spectra
in which the order of two or more residues remains ambiguous due to
lacking fragment ions for the intermediate positions, and isobaric
combinations of amino acids, of potentially different lengths, for
example, GG = N and GA = Q. Here, we present several updates to Stitch
(v1.5), which performs template-based assembly of <italic>de novo</italic> peptides to reconstruct antibody sequences. This version introduces
a mass-based alignment algorithm that explicitly accounts for mass
coincidence errors. In addition, it incorporates a postprocessing
procedure to assign I/L residues based on secondary fragments (satellite
ions, <italic>i.e.</italic>, <italic>w-</italic>ions). Moreover, evidence
for sequence assignments can now be directly evaluated with the addition
of an integrated spectrum viewer. Lastly, input data from a wider
selection of <italic>de novo</italic> peptide sequencing algorithms
are allowed, now including Casanovo, PEAKS, Novor.Cloud, pNovo, and
MaxNovo, in addition to flat text and FASTA. Combined, these changes
make Stitch compatible with a larger range of data processing pipelines
and improve its tolerance to peptide-level sequencing errors.</p>
    </abstract>
    <kwd-group>
      <kwd>mass spectrometry</kwd>
      <kwd><italic>de novo</italic> sequencing</kwd>
      <kwd>sequence assembly</kwd>
      <kwd>antibodies</kwd>
      <kwd>alignment</kwd>
      <kwd>isobaric</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>HORIZON EUROPE European Research Council</institution>
            <institution-id institution-id-type="doi">10.13039/100019180</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>101077640</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Exacte en Natuurwetenschappen</institution>
            <institution-id institution-id-type="doi">10.13039/501100024870</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>024.002.009</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>pr4c00188</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>pr4c00188</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Antibodies are essential components of
the adaptive immune system
that can recognize a vast array of antigens in the fight against pathogens
or in autoimmune disease.<sup><xref ref-type="bibr" rid="ref1">1</xref>−<xref ref-type="bibr" rid="ref4">4</xref></sup> The diversity of antigens recognized by antibodies
is mirrored by the diversity of the antibody sequences. This diversity
is generated by somatic recombination and hypermutation of the paired
heavy and light chains, taking place in singular B cells. Studying
these unique antibody sequences therefore is crucial to understanding
the immune response in health and disease and to developing diagnostics,
therapeutics, and affinity reagents for life science research based
on antibody-mediated recognition and binding of target antigens.</p>
    <p>Established methods for antibody sequencing target the coding mRNA
in single B cells.<sup><xref ref-type="bibr" rid="ref5">5</xref>−<xref ref-type="bibr" rid="ref12">12</xref></sup> While these methods have laid the foundation for our current understanding
of the antibody response, they do not directly access the functional
secreted products found in bodily fluids in the same way as they are
probed in common serological assays (to determine the binding and
neutralization titers following natural infection or immunization).
Additionally, B cells reside in the spleen, bone marrow, and blood,
of which only the latter population can be easily sampled in human
subjects. In contrast, mass spectrometry-based methods can probe specific
antibody sequences directly from the secreted polypeptide product,
thereby circumventing the need to sample the antibody-producing B-cell
clone and providing a direct glimpse into the so-called serum compartment
of the immunoglobulin repertoire.<sup><xref ref-type="bibr" rid="ref13">13</xref>−<xref ref-type="bibr" rid="ref26">26</xref></sup></p>
    <p>Using a bottom-up proteomics approach, accurate peptide sequences
can be determined and assembled into complete heavy- and light-chain
sequences. We have recently developed the software tool Stitch to
perform template-based assembly of peptide sequences against the coding
gene segments of antibodies available in immunogenetics databases.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Stitch has been shown to enable the accurate
reconstruction of monoclonal antibody sequences, as well as the sequencing
of isolated Fab fragments from patient serum, M-proteins in monoclonal
gammopathies, antibody light chains from urine, and the profiling
of whole IgG from COVID-19 patient sera.<sup><xref ref-type="bibr" rid="ref13">13</xref>−<xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup> Sequence accuracies of ∼99% can be obtained,
which is sufficient to reverse engineer functional antibody products.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> Remaining sequencing errors stem in large parts from common mass
coincidences of isobaric residues like leucine/isoleucine but also
from incomplete fragmentation spectra in which the order of two or
more residues remains ambiguous due to lacking fragment ions for the
intermediate positions. Likewise, different combinations of amino
acids, of potentially different lengths, can also coincide to the
same mass (e.g., GG=N, GA=Q). In addition to limiting
the accuracy of the input peptide sequences, these mass coincidence
errors may also hamper proper assembly of the short peptides against
the antibody template sequences.</p>
    <p>Here, we discuss several recent
updates to Stitch (v1.1 up to and
including v1.5) in light of common MS-based <italic>de novo</italic> sequencing errors. These updates include a mass-based alignment
algorithm (akin to Meta-SPS-contig<sup><xref ref-type="bibr" rid="ref30">30</xref></sup>),
a post-processing procedure to assign I/L residues based on secondary
fragments, a built-in spectrum viewer, a graph-based analysis that
tracks the connectivity between identified sequence variants, and
the ability to use a wider selection of <italic>de novo</italic> peptide
sequencing programs as input, including Casanovo, MaxNovo, Novor.Cloud,
PEAKS, and pNovo.<sup><xref ref-type="bibr" rid="ref31">31</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> Combined, these changes make Stitch compatible with a larger range
of data processing pipelines and improve its tolerance to peptide-level
sequencing errors.</p>
  </sec>
  <sec id="sec2">
    <title>Methods</title>
    <sec id="sec2.1">
      <title>Mass Coincidence Rate</title>
      <p>The mass coincidence rates over
different precisions and mass ranges (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A,B) were calculated by generating all possible
amino acid sequences from the canonical amino acids for each mass
range (without rotations), including the following modifications:
Carbamidomethyl (fixed on C), Oxidation (variable on WHM), Deamidated
(variable on NQ), Glu → pyro-Glu (variable on N-term E), and
Gln → pyro-Glu (variable on N-term Q). For each of these sets
of possible sequences, the number of unique masses was calculated
by going through the possible sets sorted on mass and greedily combining
any set with the previous if within the given precision.</p>
    </sec>
    <sec id="sec2.2">
      <title>Smith-Waterman
Comparison to Mass-Based Alignment</title>
      <p>The
comparison between Smith–Waterman alignment (SWA) and mass-based
alignment (MBA) (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A) was made by running Stitch with different PEAKS ALC peptide cutoff
scores. The other parameters used were enforce unique 0.9, cutoff
score template matching 5, cutoff score recombination 5, with the
default templates for <italic>Homo sapiens</italic> heavy
and light chains, and common contaminants. The identity was determined
using a version of MBA by comparing the consensus sequence as given
by these runs to the known sequence. The coverage was determined by
counting the fractions of positions that had at least one peptide
matching as given in the Stitch FASTA export.</p>
      <p>The average scores
for each ALC bin (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B) were calculated using the Herceptin data at PEAKS ALC cutoff
50 from <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A.
The score was normalized by dividing the absolute score by the length
of each peptide it matched on the template. These scores were grouped
by ALC of the peptide, and the average and standard deviation were
calculated.</p>
    </sec>
    <sec id="sec2.3">
      <title>Accuracy/Error Estimates</title>
      <p>The likelihood
of a given
number of mistakes (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>) was calculated following a simple binomial model, in which
the probability <italic>P</italic>(<italic>C</italic>, <italic>T</italic>) of obtaining <italic>C</italic> correct amino acids in a sequence
of length <italic>T,</italic> with a given accuracy <italic>a</italic>, equals <italic>a</italic><sup><italic>C</italic></sup> × (1
– <italic>a</italic>)<sup><italic>T</italic>−<italic>C</italic></sup>, which can be simplified to <italic>a</italic><sup><italic>T</italic></sup> when <italic>C</italic> equals <italic>T</italic>, meaning no mistakes are made, which can then be solved for <italic>a</italic> as <inline-formula id="d34e285"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_m001.gif"/></inline-formula>.</p>
    </sec>
    <sec id="sec2.4">
      <title>Accuracy
of I/L Assignments</title>
      <p>The accuracy at I/L positions
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B) was determined
by running Stitch with the same data as the SWA vs MBA comparison,
with PEAKS cutoff ALC 95, enforce unique 0.9, template matching and
recombine cutoff score 10, mass-based alignment, the default templates
for <italic>Homo sapiens</italic> heavy and light chain,
and common contaminants, the raw data, and by turning on XleDisambiguation
on the input file. For each I/L location, the known true sequence,
Stitch outcome, and germline sequence were compared.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Results</title>
    <p>Stitch assembles peptides from <italic>de novo</italic> sequencing
programs for bottom-up LC-MS/MS data in the correct framework of the
heavy and light chains of an antibody. An outline of the assembly
and processing performed by Stitch, including the new features described
here, is presented in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. The previously published version of Stitch was already able
to handle PEAKS, FASTA, and plain text data, which is now extended
to include the output from Casanovo, MaxNovo, Novor.Cloud, and pNovo.<sup><xref ref-type="bibr" rid="ref31">31</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> These peptides are aligned to the germline sequences of the corresponding
gene segments (V/J/C) for the appropriate species and placed when
the alignment score exceeds a user-defined cutoff. The consensus sequence
for a single template is made from all placed peptides, weighed for
the confidence and abundance of the individually placed peptides as
reported by the peptide <italic>de novo</italic> sequencing programs.
This procedure robustly places peptide reads in the correct framework
of the full antibody sequence except for the hypervariable Complementarity
Determining Region 3 of the heavy chain (CDRH3). CDRH3 is formed by
the junction of three coding gene segments V, D, and J, of which D
is exceptionally short and variable, such that germline sequences
do not provide a functional template to guide the assembly. Instead,
Stitch extends the flanking V- and J-segments with a user-defined
number of wildcard “X” characters, such that overhanging
reads from the V- and J-segments can be used to extend the consensus
sequence into the CDRH3 region. The resulting overhanging V- and J-sequences
are then aligned to find the overlap from both sides to reconstruct
CDRH3. In contrast, CDR3 of the light chain is encoded only with V-
and J-segments and can typically be reconstructed from the first-order
template matching step alone. These consensus sequences of the recombined
V- and J-segments are then used for a second template matching step
to reconstruct the final consensus sequence of the antibody. It should
be noted that this procedure is only suitable for monoclonal antibodies
(although it is tolerant to a moderate background of polyclonal sequences).<sup><xref ref-type="bibr" rid="ref13">13</xref>−<xref ref-type="bibr" rid="ref15">15</xref></sup> The reconstruction of CDRH3 from disperse polyclonal mixtures currently
requires manual curation of the candidate sequences. The template-based
assembly (and recombination) results of Stitch are written out as
an interactive report where all peptide alignments can be inspected,
and overview statistics like total score/area are collected for every
template sequence. To aid in the analysis of disperse polyclonal mixtures,
this new version of Stitch introduces the so-called “variant
graph”, which shows how co-occurring sequence variations in
reference to the templates are connected by peptide reads.</p>
    <fig id="fig1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Overview of
the program Stitch.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0001" id="gr1" position="float"/>
    </fig>
    <p>We also introduced a
fundamentally different alignment algorithm
for the placement of input reads against template sequences. We previously
used a modified version of the Smith–Waterman algorithm (SWA)
using a matrix based on BLOSUM62.<sup><xref ref-type="bibr" rid="ref39">39</xref>−<xref ref-type="bibr" rid="ref41">41</xref></sup> The SWA only accounts
for mismatches between input reads and template sequences that stem
from evolutionary processes like somatic hypermutation observed in
mature antibody sequences compared to the germline precursors. In
our experimental data, however, these mismatches are further convoluted,
with errors inherent to an MS-based approach to peptide sequencing.</p>
    <p>To illustrate the sequencing errors that MS is prone to, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A plots the residue masses of the 20 common amino acids (with
common modifications) on a scale of 50 to 200 Da, also including the
amino acid combinations that fall within this range. Considering that
mass analyzers in current proteomics setups typically operate within
a precision range of 0.01–0.50 Da, we can broadly distinguish
between four categories of MS-based sequencing errors. The first category
is the isobaric residues isoleucine and leucine, which simply have
identical masses and cannot be distinguished without the presence
of secondary fragment ions (as further discussed below). The second
category of common MS-based errors includes larger isobaric <italic>sets</italic> of amino acids, where different combinations of residues
amount to identical masses and cannot be distinguished. This second
category stems from missing fragment ions in the MS/MS spectra. There
are three subcategories of errors in this second category: (a) simple
rotations within a set (e.g., AS = SA), b) isobaric sets (e.g., AS
= GT), and (c) isobaric sets of different lengths (e.g., N = GG, Q
= GA). For sets of three residues or more, combinations of these subcategories
may occur. The third category of common MS-based errors includes (modified)
residues that are not strictly identical in mass but are so similar
that they cannot be distinguished, given the experimental precision
limits of the mass analyzer. For instance, the mass difference between
K and Q is 0.036 Da, between M<sup>ox</sup> and F 0.033 Da. This third
category of MS-based errors can be eliminated with the use of a high-precision
mass analyzer (TOF, FT-MS), but it poses a significant limitation
to <italic>de novo</italic> sequencing at lower precision (ion trap).
The fourth category of common MS-based errors does not necessarily
stem from analytical limitations but rather from artifacts of the
sample processing pipeline in the form of deamidation of Q and especially
N, converting these residues to E and D, respectively.</p>
    <fig id="fig2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Mass coincidence errors
in de novo peptide sequencing. (A) All
possible amino acid sequences up to 200 Da, including common modifications
(carbamidomethyl fixed on C, pyro-Glu, deamidation on N and Q, and
oxidation on M and H). (B) The fraction of sequences that can be told
apart (specificity) is based on the precision in Da and the upper
mass limit (not counting rotations). (C) Illustration of how the mass-based
alignment provides a better handle on mass coincidence errors.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0002" id="gr2" position="float"/>
    </fig>
    <p><xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B illustrates
how these common MS-based errors accumulate as a function of precision
for progressively larger mass intervals (i.e., a higher number of
missing fragments). A few obvious but fundamental requirements and
limitations for <italic>de novo</italic> peptide sequencing can be
observed from this “survival” analysis, showing what
fraction of possible unique residues (or residue combinations) can
be distinguished based on their mass, not counting rotations. First,
it is of the utmost importance to achieve complete fragmentation as
category 2 errors (isobaric subsets) readily accumulate over larger
mass intervals. Second, category 3 errors (similar residue masses)
can be eliminated with high precision mass analyzers. Important to
note is that the required precision to eliminate category 3 errors
is readily achieved on modern mass analyzers for small peptide fragments
with low charge states but that this becomes a significant limitation
for larger fragments with higher charge states in middle- and top-down
approaches. Considering these common MS-based errors, we propose here
a modification of the SWA to perform the template-based assembly for
antibody sequencing.</p>
    <p>One of the most important drawbacks in
the context of these MS-based
errors is that in SWA, a substitution can only be a single amino acid
to another single amino acid while the category 2 errors affect multiple
consecutive residues. The new mass-based alignment we devised considers
these errors by aligning not only single amino acids but also larger
sets, illustrated in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C. It does this by supplementing the alignment steps looked
for in SWA (i.e., match/mismatch/insertion/deletion), with two additional
steps: rotation and isobaric. These last two steps can be of length
up to <italic>N</italic> steps on both the template and peptide (e.g.,
match 2 amino acids on the template with 3 on the input peptide).
With this addition, the category 2 errors, up to N amino acids, can
easily be found. The score for each aligned set of amino acids is
looked up in a premade two-dimensional array with the same modified
BLOSUM62 base matrix in the top left and all category 2 errors given
a nonzero score in the array based on their mass identity. It is important
for the behavior of the alignment that these rotations and isobaric
matches score lower than any direct match. Hence, rotations score
3 per amino acid involved and isobaric matches score 2 per the maximum
number of amino acids involved. The alignment algorithm looks for
any nonzero score in the set of steps of up to <italic>N</italic> residues,
alongside the normal cases for SWA, and the highest scoring of the
possible steps is chosen. This approach is similar to Meta-SPS contig,
with the main difference that alignment and assembly is performed
on the level of the output peptide sequences, rather than the MS/MS
data itself.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup></p>
    <p>Use of the mass-based
alignment (MBA) versus SWA improves the tolerance
to mass coincidence errors during template-based assembly. This difference
is illustrated in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> using PEAKS input data for the two monoclonal antibodies
Herceptin and F59. PEAKS provides a peptide-level average local confidence
(ALC) score between 0 and 99, where peptides with a lower ALC typically
miss more fragment ions to support the given sequence. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A shows how the average length-normalized alignment score
during the assembly develops as a function of the ALC cutoff for MBA
vs SWA. By design, the alignment scores are consistently higher using
MBA vs SWA, the margin illustrating just how common mass coincidence
errors are in the input data. The higher degrees of freedom in MBA
evidently allow for better placement of the input reads, while we
see no signs of overfitting, even at the relatively low alignment
score cutoff of 5 used in this analysis. Peptides with higher ALC
(and fewer errors) yield higher alignment scores, as expected, but
to achieve optimal accuracy in the final consensus sequences, there
is an important trade-off to be made between selection of the highest-scoring
input reads and achieving optimal coverage. As the coverage plummets
with ALC cutoff scores &gt;95, it follows that a substantial tolerance
to mass coincidence errors is required to assemble the complete sequences
(given the limitations of the experimental input data) by including
lower ALC (&lt;95) peptides (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). Of note, SWA cannot align any peptides below ALC
55, while these may still be placed using MBA.</p>
    <fig id="fig3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Mass-based alignment
results. (A) Average normalized score (score/alignment
length) as a function of PEAKS ALC. Note that the missing points for
CutoffALC &lt; 55 for Smith–Waterman alignment is because no
peptides with these scores could be placed by this alignment algorithm.
(B) Result of running Stitch with the Herceptin and F59 sample data
with different read cutoff scores presented as accuracy, defined here
as identity against the true sequence, in a solid line, and coverage,
the fraction of positions covered by at least one peptide, drawn in
a dotted line. Note that the results were generated running Stitch
with a low cutoff score for template matching. (C) An excerpt of the
alignment of the highest scoring light chain variable gene from the
Stitch report for Herceptin using mass-based alignment and CutoffALC
85.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0003" id="gr3" position="float"/>
    </fig>
    <p>The accuracy of the final consensus
sequences of Herceptin and
F59 is plotted as a function of ALC cutoff in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B, illustrating that MBA outperforms SWA
across the sampled range. The accuracy increases from 0.95 (SWA) to
0.99 (MBA). While this may seem like a moderate increase at first,
it represents a better than 100-fold improvement in the probability
to determine the sequence of a 120 amino acid long variable domain
with zero mistakes (<italic>P</italic> = 0.002 for accuracy 0.95 vs <italic>P</italic> = 0.299 for accuracy 0.99). Of note, to achieve a probability
of <italic>P</italic> &gt; 0.99 to make zero mistakes in a sequence
of
this length, the accuracy needs to further improve to &gt;0.9999 (see <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>).</p>
    <fig id="fig4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Probability of the indicated number of errors in a sequence of
120 amino acids given the sequencing accuracy per amino acid.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0004" id="gr4" position="float"/>
    </fig>
    <p>In addition to the new MBA, Stitch is also updated
to read and
display fragmentation spectra in an interactive spectrum viewer (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A). This allows the user to manually inspect the underlying
data for an assigned sequence. Moreover, accessing the fragmentation
spectra in Stitch also allowed us to implement a new postprocessing
procedure to differentiate between leucine/isoleucine based on secondary
fragment ions that can be observed in some fragmentation modes, notably
electron transfer high energy collision dissociation data.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> These diagnostic satellite ions (known as <italic>w</italic>/<italic>d</italic>-ions) are formed by secondary fragmentation
of <italic>z-</italic> and <italic>a-</italic>ions, by transfer of
the free electron to the side chain, and breaking of a bond to the
first C atom in the side chain (Cβ). As the side chains are
different between isoleucine and leucine, the possible mass shifts
of the satellite ions are different, being 15 and 29 Da for isoleucine
(loss of C<sub>1</sub>H<sub>3</sub> and C<sub>2</sub>H<sub>5</sub>) and 43 Da for leucine (loss of C<sub>3</sub>H<sub>7</sub>). Stitch
gives the option to use these satellite ions to find the most likely
candidate for each I/L position. This improves the fraction of correctly
identified I/L positions from 0.81 (when defaulting to the germline
template sequence or to L in the case of newly introduced I/L mutations)
to 0.94 when using the satellite ions, as seen in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B.</p>
    <fig id="fig5" position="float">
      <label>Figure 5</label>
      <caption>
        <p>Satellite ion usage to
identify I/L. (A) Screenshot from the spectrum
viewer of a CDRH3 peptide of Herceptin. (B) The fraction of correct
I/L identifications using just the germline (previous version of Stitch)
or the new satellite ions; alignment identity is used as measure of
accuracy. (C) An example spectrum with satellite ions annotated as
Stitch would display it.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0005" id="gr5" position="float"/>
    </fig>
  </sec>
  <sec id="sec4">
    <title>Discussion</title>
    <p>These
recent updates to Stitch provide a better handle on mass
coincidence errors for <italic>de novo</italic> antibody sequencing
by LC-MS/MS. These improvements extend to any MS-based <italic>de
novo</italic> sequencing application beyond antibodies, and indeed,
Stitch can perform the same tasks on an arbitrary set of template
sequences.</p>
    <p>Implementation of the mass-based alignment shed light
on fundamental
requirements and limitations for MS-based <italic>de novo</italic> sequencing and set out some important goals for the near future.
To minimize peptide-level sequencing errors, it is crucially important
to analyze at a precision of at least 0.02 Da, achieve complete fragmentation,
and obtain secondary fragment ions to differentiate I/L. The latter
two points call for use of complementary fragmentation techniques
beyond CID. Currently, accuracies of 0.99 can be achieved on the consensus
sequence level, but to achieve a milestone 99% confidence in error-free
sequences, this needs to improve to &gt;0.9999 for the case of an
antibody
variable domain of 120 amino acids. Based on our own work, this requires
further improvement of I/L assignments, but even more so elimination
of deamidation errors (primarily N/D) from the sample processing workflows.
Moreover, the 0.99 accuracy is currently based on consensus sequences
from overlapping peptides, and as we expand applications to complex
polyclonal antibody mixtures, the depth of coverage will inevitably
suffer, again calling for improved fragmentation to minimize sequencing
errors at the peptide level. In addition to improved fragmentation,
recent improvements in retention time prediction may also be leveraged
in <italic>de novo</italic> peptide sequencing algorithms to improve
peptide-level sequence accuracy.<sup><xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup></p>
    <p>Stitch
is now compatible with a wide range of current de novo sequencing
algorithms, providing an improved strategy for sequence assembly with
mass-based alignment and the opportunity to browse spectrum-level
evidence for the determined sequence to aid in manual curation. It
is a versatile tool for MS-based antibody sequencing and beyond and
may provide a springboard to dive into the serum compartment of the
antibody repertoire with proteomics techniques.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes1">
    <title>Data Availability Statement</title>
    <p>The source code
of Stitch is available on GitHub: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/snijderlab/stitch">https://github.com/snijderlab/stitch</uri>. All Stitch HTML results related to this study are provided as Supporting
Data. The raw data of the monoclonal antibodies Herceptin and F59
are available under identifier PXD023419 and doi 10.6084/m9.figshare.13194005,
respectively.</p>
  </notes>
  <notes id="notes2" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00188?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00188</ext-link>.<list id="silist" list-type="simple"><list-item><p>Isobaric statistics;
mass-based benchmark, and xln disambiguation
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.4c00188/suppl_file/pr4c00188_si_001.zip">ZIP</ext-link>)</p></list-item><list-item><p>All
Stitch HTML results related to this study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.4c00188/suppl_file/pr4c00188_si_002.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_si_001.zip">
        <caption>
          <p>pr4c00188_si_001.zip</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_si_002.pdf">
        <caption>
          <p>pr4c00188_si_002.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d14e516-autogenerated">
    <p>The authors declare no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>The authors thank Bastiaan
de Graaf for the fruitful
discussions regarding the design of Stitch and the mass-based alignment
algorithm. We would also like to thank Lukas Käll for helpful
input and feedback on the manuscript. This research was funded by
the Dutch Research Council NWO Gravitation 2013 BOO, Institute for
Chemical Immunology (ICI; 024.002.009), and the European Research
Council Executive Agency HORIZON ERC-2022-STG (FLAVIR; 101077640).</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Casadevall</surname><given-names>A.</given-names></name>; <name><surname>Pirofski</surname><given-names>L.</given-names></name><article-title>A New Synthesis for
Antibody-Mediated Immunity</article-title>. <source>Nat. Immunol</source><year>2012</year>, <volume>13</volume> (<issue>1</issue>), <fpage>21</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2184</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Davies</surname><given-names>D. R.</given-names></name>; <name><surname>Metzger</surname><given-names>H.</given-names></name><article-title>Structural Basis of
Antibody Function</article-title>. <source>Annu. Rev. Immunol.</source><year>1983</year>, <volume>1</volume> (<issue>1</issue>), <fpage>87</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.iy.01.040183.000511</pub-id>.<pub-id pub-id-type="pmid">6399980</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Lleo</surname><given-names>A.</given-names></name>; <name><surname>Invernizzi</surname><given-names>P.</given-names></name>; <name><surname>Gao</surname><given-names>B.</given-names></name>; <name><surname>Podda</surname><given-names>M.</given-names></name>; <name><surname>Gershwin</surname><given-names>M. E.</given-names></name><article-title>Definition
of Human Autoimmunity — Autoantibodies versus Autoimmune Disease</article-title>. <source>Autoimmun Rev.</source><year>2010</year>, <volume>9</volume> (<issue>5</issue>), <fpage>A259</fpage>–<lpage>A266</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2009.12.002</pub-id>.<pub-id pub-id-type="pmid">19963079</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Naparstek</surname><given-names>Y.</given-names></name>; <name><surname>Plotz</surname><given-names>P. H.</given-names></name><article-title>The Role of Autoantibodies
in Autoimmune Disease</article-title>. <source>Annu. Rev. Immunol.</source><year>1993</year>, <volume>11</volume> (<issue>1</issue>), <fpage>79</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.iy.11.040193.000455</pub-id>.<pub-id pub-id-type="pmid">8476578</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Avram</surname><given-names>O.</given-names></name>; <name><surname>Kigel</surname><given-names>A.</given-names></name>; <name><surname>Vaisman-Mentesh</surname><given-names>A.</given-names></name>; <name><surname>Kligsberg</surname><given-names>S.</given-names></name>; <name><surname>Rosenstein</surname><given-names>S.</given-names></name>; <name><surname>Dror</surname><given-names>Y.</given-names></name>; <name><surname>Pupko</surname><given-names>T.</given-names></name>; <name><surname>Wine</surname><given-names>Y.</given-names></name><article-title>PASA: Proteomic
Analysis of Serum Antibodies Web Server</article-title>. <source>PLoS
Comput. Biol.</source><year>2021</year>, <volume>17</volume> (<issue>1</issue>), <elocation-id>e1008607</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008607</pub-id>.<pub-id pub-id-type="pmid">33493161</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Lavinder</surname><given-names>J. J.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name><article-title>Next-Generation
Sequencing and Protein Mass Spectrometry for the Comprehensive Analysis
of Human Cellular and Serum Antibody Repertoires</article-title>. <source>Curr. Opin Chem. Biol.</source><year>2015</year>, <volume>24</volume>, <fpage>112</fpage>–<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2014.11.007</pub-id>.<pub-id pub-id-type="pmid">25461729</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Chromikova</surname><given-names>V.</given-names></name>; <name><surname>Joyce</surname><given-names>M. G.</given-names></name>; <name><surname>Vollmers</surname><given-names>C.</given-names></name>; <name><surname>Leung</surname><given-names>K.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>DeKosky</surname><given-names>B. J.</given-names></name>; <name><surname>Lee</surname><given-names>C.-H.</given-names></name>; <name><surname>Lavinder</surname><given-names>J. J.</given-names></name>; <name><surname>Murrin</surname><given-names>E. M.</given-names></name>; <name><surname>Chrysostomou</surname><given-names>C.</given-names></name>; <name><surname>Hoi</surname><given-names>K. H.</given-names></name>; <name><surname>Tsybovsky</surname><given-names>Y.</given-names></name>; <name><surname>Thomas</surname><given-names>P. V.</given-names></name>; <name><surname>Druz</surname><given-names>A.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Kong</surname><given-names>W.-P.</given-names></name>; <name><surname>Park</surname><given-names>D.</given-names></name>; <name><surname>Popova</surname><given-names>L. I.</given-names></name>; <name><surname>Dekker</surname><given-names>C. L.</given-names></name>; <name><surname>Davis</surname><given-names>M. M.</given-names></name>; <name><surname>Carter</surname><given-names>C. E.</given-names></name>; <name><surname>Ross</surname><given-names>T. M.</given-names></name>; <name><surname>Ellington</surname><given-names>A. D.</given-names></name>; <name><surname>Wilson</surname><given-names>P. C.</given-names></name>; <name><surname>Marcotte</surname><given-names>E. M.</given-names></name>; <name><surname>Mascola</surname><given-names>J. R.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name>; <name><surname>Krammer</surname><given-names>F.</given-names></name>; <name><surname>Quake</surname><given-names>S. R.</given-names></name>; <name><surname>Kwong</surname><given-names>P. D.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name><article-title>Molecular-Level
Analysis of the Serum Antibody Repertoire in Young Adults before and
after Seasonal Influenza Vaccination</article-title>. <source>Nat. Med.</source><year>2016</year>, <volume>22</volume> (<issue>12</issue>), <fpage>1456</fpage>–<lpage>1464</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4224</pub-id>.<pub-id pub-id-type="pmid">27820605</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Paparoditis</surname><given-names>P.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>Frühwirth</surname><given-names>A.</given-names></name>; <name><surname>McDaniel</surname><given-names>J. R.</given-names></name>; <name><surname>Jung</surname><given-names>J.</given-names></name>; <name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Hussein</surname><given-names>D. A.</given-names></name>; <name><surname>Tanno</surname><given-names>Y.</given-names></name>; <name><surname>Pappas</surname><given-names>L.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name>; <name><surname>Corti</surname><given-names>D.</given-names></name>; <name><surname>Lanzavecchia</surname><given-names>A.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name><article-title>Persistent Antibody Clonotypes Dominate
the Serum Response to Influenza over Multiple Years and Repeated Vaccinations</article-title>. <source>Cell Host Microb.</source><year>2019</year>, <volume>25</volume> (<issue>3</issue>), <fpage>367</fpage>–<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2019.01.010</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Lindesmith</surname><given-names>L. C.</given-names></name>; <name><surname>McDaniel</surname><given-names>J. R.</given-names></name>; <name><surname>Changela</surname><given-names>A.</given-names></name>; <name><surname>Verardi</surname><given-names>R.</given-names></name>; <name><surname>Kerr</surname><given-names>S. A.</given-names></name>; <name><surname>Costantini</surname><given-names>V.</given-names></name>; <name><surname>Brewer-Jensen</surname><given-names>P. D.</given-names></name>; <name><surname>Mallory</surname><given-names>M. L.</given-names></name>; <name><surname>Voss</surname><given-names>W. N.</given-names></name>; <name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Blazeck</surname><given-names>J. J.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name>; <name><surname>Vinje</surname><given-names>J.</given-names></name>; <name><surname>Kwong</surname><given-names>P. D.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name>; <name><surname>Baric</surname><given-names>R. S.</given-names></name><article-title>Sera Antibody Repertoire
Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing
Responses after Human Norovirus Vaccination</article-title>. <source>Immunity</source><year>2019</year>, <volume>50</volume> (<issue>6</issue>), <fpage>1530</fpage>–<lpage>1541</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2019.05.007</pub-id>.<pub-id pub-id-type="pmid">31216462</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>Wine</surname><given-names>Y.</given-names></name>; <name><surname>Lavinder</surname><given-names>J. J.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name>; <name><surname>Marcotte</surname><given-names>E. M.</given-names></name><article-title>Proteomic Identification of Monoclonal Antibodies from
Serum</article-title>. <source>Anal. Chem.</source><year>2014</year>, <volume>86</volume> (<issue>10</issue>), <fpage>4758</fpage>–<lpage>4766</lpage>. <pub-id pub-id-type="doi">10.1021/ac4037679</pub-id>.<pub-id pub-id-type="pmid">24684310</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Ellebrecht</surname><given-names>C. T.</given-names></name>; <name><surname>Mukherjee</surname><given-names>E. M.</given-names></name>; <name><surname>Zheng</surname><given-names>Q.</given-names></name>; <name><surname>Choi</surname><given-names>E. J.</given-names></name>; <name><surname>Reddy</surname><given-names>S. G.</given-names></name>; <name><surname>Mao</surname><given-names>X.</given-names></name>; <name><surname>Payne</surname><given-names>A. S.</given-names></name><article-title>Autoreactive IgG and IgA B Cells Evolve through Distinct
Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris</article-title>. <source>Cell Rep</source><year>2018</year>, <volume>24</volume> (<issue>9</issue>), <fpage>2370</fpage>–<lpage>2380</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.093</pub-id>.<pub-id pub-id-type="pmid">30157430</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Fridy</surname><given-names>P. C.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Keegan</surname><given-names>S.</given-names></name>; <name><surname>Thompson</surname><given-names>M. K.</given-names></name>; <name><surname>Nudelman</surname><given-names>I.</given-names></name>; <name><surname>Scheid</surname><given-names>J. F.</given-names></name>; <name><surname>Oeffinger</surname><given-names>M.</given-names></name>; <name><surname>Nussenzweig</surname><given-names>M. C.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Chait</surname><given-names>B. T.</given-names></name>; <name><surname>Rout</surname><given-names>M. P.</given-names></name><article-title>A Robust
Pipeline for Rapid Production
of Versatile Nanobody Repertoires</article-title>. <source>Nat. Methods</source><year>2014</year>, <volume>11</volume> (<issue>12</issue>), <fpage>1253</fpage>–<lpage>1260</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3170</pub-id>.<pub-id pub-id-type="pmid">25362362</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Bondt</surname><given-names>A.</given-names></name>; <name><surname>Hoek</surname><given-names>M.</given-names></name>; <name><surname>Dingess</surname><given-names>K.</given-names></name>; <name><surname>Tamara</surname><given-names>S.</given-names></name>; <name><surname>de Graaf</surname><given-names>B.</given-names></name>; <name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>den Boer</surname><given-names>M. A.</given-names></name>; <name><surname>Damen</surname><given-names>M.</given-names></name>; <name><surname>Zwart</surname><given-names>C.</given-names></name>; <name><surname>Barendregt</surname><given-names>A.</given-names></name>; <name><surname>van Rijswijck</surname><given-names>D. M. H.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Grobben</surname><given-names>M.</given-names></name>; <name><surname>Tejjani</surname><given-names>K.</given-names></name>; <name><surname>van Rijswijk</surname><given-names>J.</given-names></name>; <name><surname>Völlmy</surname><given-names>F.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name>; <name><surname>Fortini</surname><given-names>F.</given-names></name>; <name><surname>Papi</surname><given-names>A.</given-names></name>; <name><surname>Volta</surname><given-names>C. A.</given-names></name>; <name><surname>Campo</surname><given-names>G.</given-names></name>; <name><surname>Contoli</surname><given-names>M.</given-names></name>; <name><surname>van Gils</surname><given-names>M. J.</given-names></name>; <name><surname>Spadaro</surname><given-names>S.</given-names></name>; <name><surname>Rizzo</surname><given-names>P.</given-names></name>; <name><surname>Heck</surname><given-names>A. J. R.</given-names></name><article-title>Into
the Dark Serum Proteome: Personalized
Features of IgG1 and IgA1 Repertoires in Severe COVID-19 Patients</article-title>. <source>Molecular &amp; Cellular Proteomics</source><year>2024</year>, <volume>23</volume> (<issue>1</issue>), <elocation-id>100690</elocation-id><pub-id pub-id-type="doi">10.1016/j.mcpro.2023.100690</pub-id>.<pub-id pub-id-type="pmid">38065436</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>den Boer</surname><given-names>M. A.</given-names></name>; <name><surname>Tamara</surname><given-names>S.</given-names></name>; <name><surname>Mokiem</surname><given-names>N. J.</given-names></name>; <name><surname>van der
Lans</surname><given-names>S. P. A.</given-names></name>; <name><surname>Bondt</surname><given-names>A.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Haas</surname><given-names>P.-J.</given-names></name>; <name><surname>Minnema</surname><given-names>M. C.</given-names></name>; <name><surname>Rooijakkers</surname><given-names>S. H. M.</given-names></name>; <name><surname>van Zuilen</surname><given-names>A. D.</given-names></name>; <name><surname>Heck</surname><given-names>A. J. R.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Direct Mass Spectrometry-Based Detection
and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance
from Patient Serum: A Case Study</article-title>. <source>J. Proteome
Res.</source><year>2023</year>, <volume>22</volume> (<issue>9</issue>), <fpage>3022</fpage>–<lpage>3028</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.3c00330</pub-id>.<pub-id pub-id-type="pmid">37499263</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Bondt</surname><given-names>A.</given-names></name>; <name><surname>Hoek</surname><given-names>M.</given-names></name>; <name><surname>Tamara</surname><given-names>S.</given-names></name>; <name><surname>de Graaf</surname><given-names>B.</given-names></name>; <name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>van Rijswijck</surname><given-names>D. M. H.</given-names></name>; <name><surname>den Boer</surname><given-names>M. A.</given-names></name>; <name><surname>Greisch</surname><given-names>J. F.</given-names></name>; <name><surname>Varkila</surname><given-names>M. R. J.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name>; <name><surname>Cremer</surname><given-names>O. L.</given-names></name>; <name><surname>Bonten</surname><given-names>M. J. M.</given-names></name>; <name><surname>Heck</surname><given-names>A. J. R.</given-names></name><article-title>Human Plasma
IgG1 Repertoires Are Simple, Unique, and
Dynamic</article-title>. <source>Cell Syst</source><year>2021</year>, <volume>12</volume> (<issue>12</issue>), <fpage>1131</fpage>–<lpage>1143</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2021.08.008</pub-id>.<pub-id pub-id-type="pmid">34613904</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Tran</surname><given-names>N. H.</given-names></name>; <name><surname>Rahman</surname><given-names>M. Z.</given-names></name>; <name><surname>He</surname><given-names>L.</given-names></name>; <name><surname>Xin</surname><given-names>L.</given-names></name>; <name><surname>Shan</surname><given-names>B.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name><article-title>Complete De Novo Assembly of Monoclonal
Antibody Sequences</article-title>. <source>Sci. Rep</source><year>2016</year>, <volume>6</volume> (<issue>1</issue>), <fpage>31730</fpage><pub-id pub-id-type="doi">10.1038/srep31730</pub-id>.<pub-id pub-id-type="pmid">27562653</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Sousa</surname><given-names>E.</given-names></name>; <name><surname>Olland</surname><given-names>S.</given-names></name>; <name><surname>Shih</surname><given-names>H. H.</given-names></name>; <name><surname>Marquette</surname><given-names>K.</given-names></name>; <name><surname>Martone</surname><given-names>R.</given-names></name>; <name><surname>Lu</surname><given-names>Z.</given-names></name>; <name><surname>Paulsen</surname><given-names>J.</given-names></name>; <name><surname>Gill</surname><given-names>D.</given-names></name>; <name><surname>He</surname><given-names>T.</given-names></name><article-title>Primary Sequence Determination of
a Monoclonal Antibody against α-Synuclein
Using a Novel Mass Spectrometry-Based Approach</article-title>. <source>Int. J. Mass Spectrom.</source><year>2012</year>, <volume>312</volume>, <fpage>61</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijms.2011.05.005</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Sen</surname><given-names>K. I.</given-names></name>; <name><surname>Tang</surname><given-names>W. H.</given-names></name>; <name><surname>Nayak</surname><given-names>S.</given-names></name>; <name><surname>Kil</surname><given-names>Y. J.</given-names></name>; <name><surname>Bern</surname><given-names>M.</given-names></name>; <name><surname>Ozoglu</surname><given-names>B.</given-names></name>; <name><surname>Ueberheide</surname><given-names>B.</given-names></name>; <name><surname>Davis</surname><given-names>D.</given-names></name>; <name><surname>Becker</surname><given-names>C.</given-names></name><article-title>Automated
Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery</article-title>. <source>J. Am. Soc. Mass Spectrom.</source><year>2017</year>, <volume>28</volume> (<issue>5</issue>), <fpage>803</fpage>–<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1007/s13361-016-1580-0</pub-id>.<pub-id pub-id-type="pmid">28105549</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Rickert</surname><given-names>K. W.</given-names></name>; <name><surname>Grinberg</surname><given-names>L.</given-names></name>; <name><surname>Woods</surname><given-names>R. M.</given-names></name>; <name><surname>Wilson</surname><given-names>S.</given-names></name>; <name><surname>Bowen</surname><given-names>M. A.</given-names></name>; <name><surname>Baca</surname><given-names>M.</given-names></name><article-title>Combining Phage Display
with de Novo Protein Sequencing for Reverse
Engineering of Monoclonal Antibodies</article-title>. <source>MAbs</source><year>2016</year>, <volume>8</volume> (<issue>3</issue>), <fpage>501</fpage>–<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1080/19420862.2016.1145865</pub-id>.<pub-id pub-id-type="pmid">26852694</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Savidor</surname><given-names>A.</given-names></name>; <name><surname>Barzilay</surname><given-names>R.</given-names></name>; <name><surname>Elinger</surname><given-names>D.</given-names></name>; <name><surname>Yarden</surname><given-names>Y.</given-names></name>; <name><surname>Lindzen</surname><given-names>M.</given-names></name>; <name><surname>Gabashvili</surname><given-names>A.</given-names></name>; <name><surname>Adiv Tal</surname><given-names>O.</given-names></name>; <name><surname>Levin</surname><given-names>Y.</given-names></name><article-title>Database-Independent
Protein Sequencing (DiPS) Enables Full-Length de Novo Protein and
Antibody Sequence Determination</article-title>. <source>Molecular &amp;
Cellular Proteomics</source><year>2017</year>, <volume>16</volume> (<issue>6</issue>), <fpage>1151</fpage>–<lpage>1161</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.O116.065417</pub-id>.<pub-id pub-id-type="pmid">28348172</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Pronker</surname><given-names>M. F.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Mass Spectrometry-Based <italic>De
Novo</italic> Sequencing of Monoclonal Antibodies Using Multiple Proteases
and a Dual Fragmentation Scheme</article-title>. <source>J. Proteome
Res.</source><year>2021</year>, <volume>20</volume> (<issue>7</issue>), <fpage>3559</fpage>–<lpage>3566</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.1c00169</pub-id>.<pub-id pub-id-type="pmid">34121409</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Guthals</surname><given-names>A.</given-names></name>; <name><surname>Gan</surname><given-names>Y.</given-names></name>; <name><surname>Murray</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Stinson</surname><given-names>J.</given-names></name>; <name><surname>Nakamura</surname><given-names>G.</given-names></name>; <name><surname>Lill</surname><given-names>J. R.</given-names></name>; <name><surname>Sandoval</surname><given-names>W.</given-names></name>; <name><surname>Bandeira</surname><given-names>N.</given-names></name><article-title>De Novo MS/MS Sequencing
of Native Human Antibodies</article-title>. <source>J. Proteome Res.</source><year>2017</year>, <volume>16</volume> (<issue>1</issue>), <fpage>45</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00608</pub-id>.<pub-id pub-id-type="pmid">27779884</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Cheung</surname><given-names>W. C.</given-names></name>; <name><surname>Beausoleil</surname><given-names>S. A.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Sato</surname><given-names>S.</given-names></name>; <name><surname>Schieferl</surname><given-names>S. M.</given-names></name>; <name><surname>Wieler</surname><given-names>J. S.</given-names></name>; <name><surname>Beaudet</surname><given-names>J. G.</given-names></name>; <name><surname>Ramenani</surname><given-names>R. K.</given-names></name>; <name><surname>Popova</surname><given-names>L.</given-names></name>; <name><surname>Comb</surname><given-names>M. J.</given-names></name>; <name><surname>Rush</surname><given-names>J.</given-names></name>; <name><surname>Polakiewicz</surname><given-names>R. D.</given-names></name><article-title>A Proteomics
Approach for the Identification and Cloning of Monoclonal Antibodies
from Serum</article-title>. <source>Nat. Biotechnol.</source><year>2012</year>, <volume>30</volume> (<issue>5</issue>), <fpage>447</fpage>–<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2167</pub-id>.<pub-id pub-id-type="pmid">22446692</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Castellana</surname><given-names>N. E.</given-names></name>; <name><surname>McCutcheon</surname><given-names>K.</given-names></name>; <name><surname>Pham</surname><given-names>V. C.</given-names></name>; <name><surname>Harden</surname><given-names>K.</given-names></name>; <name><surname>Nguyen</surname><given-names>A.</given-names></name>; <name><surname>Young</surname><given-names>J.</given-names></name>; <name><surname>Adams</surname><given-names>C.</given-names></name>; <name><surname>Schroeder</surname><given-names>K.</given-names></name>; <name><surname>Arnott</surname><given-names>D.</given-names></name>; <name><surname>Bafna</surname><given-names>V.</given-names></name>; <name><surname>Grogan</surname><given-names>J. L.</given-names></name>; <name><surname>Lill</surname><given-names>J. R.</given-names></name><article-title>Resurrection
of a Clinical Antibody: Template Proteogenomic de Novo Proteomic Sequencing
and Reverse Engineering of an Anti-lymphotoxin-α Antibody</article-title>. <source>Proteomics</source><year>2011</year>, <volume>11</volume> (<issue>3</issue>), <fpage>395</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1002/pmic.201000487</pub-id>.<pub-id pub-id-type="pmid">21268269</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Bandeira</surname><given-names>N.</given-names></name>; <name><surname>Pham</surname><given-names>V.</given-names></name>; <name><surname>Pevzner</surname><given-names>P.</given-names></name>; <name><surname>Arnott</surname><given-names>D.</given-names></name>; <name><surname>Lill</surname><given-names>J. R.</given-names></name><article-title>Automated
de Novo Protein Sequencing of Monoclonal Antibodies</article-title>. <source>Nat. Biotechnol.</source><year>2008</year>, <volume>26</volume> (<issue>12</issue>), <fpage>1336</fpage>–<lpage>1338</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1208-1336</pub-id>.<pub-id pub-id-type="pmid">19060866</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Giesbers</surname><given-names>K. C.</given-names></name>; <name><surname>Šiborová</surname><given-names>M.</given-names></name>; <name><surname>Beugelink</surname><given-names>J. W.</given-names></name>; <name><surname>Pronker</surname><given-names>M. F.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Hilkens</surname><given-names>J.</given-names></name>; <name><surname>Janssen</surname><given-names>B. J.</given-names></name>; <name><surname>Strijbis</surname><given-names>K.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Reverse-Engineering
the Anti-MUC1
Antibody 139H2 by Mass Spectrometry–Based de Novo Sequencing</article-title>. <source>Life Sci. Alliance</source><year>2024</year>, <volume>7</volume> (<issue>6</issue>), <elocation-id>e202302366</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.202302366</pub-id>.<pub-id pub-id-type="pmid">38508723</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Template-Based
Assembly of Proteomic
Short Reads For <italic>De Novo</italic> Antibody Sequencing and Repertoire
Profiling</article-title>. <source>Anal. Chem.</source><year>2022</year>, <volume>94</volume> (<issue>29</issue>), <fpage>10391</fpage>–<lpage>10399</lpage>. <pub-id pub-id-type="doi">10.1021/acs.analchem.2c01300</pub-id>.<pub-id pub-id-type="pmid">35834437</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Giesbers</surname><given-names>K. C. A. P.</given-names></name>; <name><surname>Šiborová</surname><given-names>M.</given-names></name>; <name><surname>Beugelink</surname><given-names>J. W.</given-names></name>; <name><surname>Pronker</surname><given-names>M. F.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Hilkens</surname><given-names>J.</given-names></name>; <name><surname>Janssen</surname><given-names>B. J. C.</given-names></name>; <name><surname>Strijbis</surname><given-names>K.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Reverse Engineering the Anti-MUC1
Hybridoma Antibody 139H2 by Mass Spectrometry-Based de Novo Sequencing</article-title>. <source>bioRxiv</source><year>2023</year>, <pub-id pub-id-type="doi">10.1101/2023.07.05.547778</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Ivanov</surname><given-names>D. G.</given-names></name>; <name><surname>Ivetic</surname><given-names>N.</given-names></name>; <name><surname>Du</surname><given-names>Y.</given-names></name>; <name><surname>Nguyen</surname><given-names>S. N.</given-names></name>; <name><surname>Le</surname><given-names>S. H.</given-names></name>; <name><surname>Favre</surname><given-names>D.</given-names></name>; <name><surname>Nazy</surname><given-names>I.</given-names></name>; <name><surname>Kaltashov</surname><given-names>I. A.</given-names></name><article-title>Reverse
Engineering of a Pathogenic Antibody Reveals the Molecular Mechanism
of Vaccine-Induced Immune Thrombotic Thrombocytopenia</article-title>. <source>J. Am. Chem. Soc.</source><year>2023</year>, <volume>145</volume> (<issue>46</issue>), <fpage>25203</fpage>–<lpage>25213</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.3c07846</pub-id>.<pub-id pub-id-type="pmid">37949820</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Guthals</surname><given-names>A.</given-names></name>; <name><surname>Clauser</surname><given-names>K. R.</given-names></name>; <name><surname>Bandeira</surname><given-names>N.</given-names></name><article-title>Shotgun Protein
Sequencing with Meta-Contig
Assembly</article-title>. <source>Molecular &amp; Cellular Proteomics</source><year>2012</year>, <volume>11</volume> (<issue>10</issue>), <fpage>1084</fpage>–<lpage>1096</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M111.015768</pub-id>.<pub-id pub-id-type="pmid">22798278</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="undeclared" id="cit31"><person-group person-group-type="allauthors"><name><surname>Yilmaz</surname><given-names>M.</given-names></name>; <name><surname>Fondrie</surname><given-names>W. E.</given-names></name>; <name><surname>Bittremieux</surname><given-names>W.</given-names></name>; <name><surname>Oh</surname><given-names>S.</given-names></name>; <name><surname>Noble</surname><given-names>W. S.</given-names></name></person-group><source>De Novo Mass Spectrometry Peptide
Sequencing with a Transformer Model</source>. <publisher-name>PMLR
June</publisher-name><volume>28</volume>, <year>2022</year>; pp <fpage>25514</fpage>–<lpage>25522</lpage>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://proceedings.mlr.press/v162/yilmaz22a.html">https://proceedings.mlr.press/v162/yilmaz22a.html</uri> (accessed 2024–01–30).</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Yilmaz</surname><given-names>M.</given-names></name>; <name><surname>Fondrie</surname><given-names>W. E.</given-names></name>; <name><surname>Bittremieux</surname><given-names>W.</given-names></name>; <name><surname>Nelson</surname><given-names>R.</given-names></name>; <name><surname>Ananth</surname><given-names>V.</given-names></name>; <name><surname>Oh</surname><given-names>S.</given-names></name>; <name><surname>Noble</surname><given-names>W. S.</given-names></name>; <name><surname>Allen</surname><given-names>P. G.</given-names></name><article-title>Sequence-to-Sequence Translation
from Mass Spectra to Peptides with a Transformer Model</article-title>. <source>bioRxiv</source><year>2023</year>, <pub-id pub-id-type="doi">10.1101/2023.01.03.522621</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Gutenbrunner</surname><given-names>P.</given-names></name>; <name><surname>Kyriakidou</surname><given-names>P.</given-names></name>; <name><surname>Welker</surname><given-names>F.</given-names></name>; <name><surname>Cox</surname><given-names>J.</given-names></name><article-title>Spectrum Graph-Based
de-Novo Sequencing Algorithm MaxNovo Achieves High Peptide Identification
Rates in Collisional Dissociation MS/MS Spectra</article-title>. <source>bioRxiv</source><year>2021</year>, <pub-id pub-id-type="doi">10.1101/2021.09.04.458985</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Ma</surname><given-names>B.</given-names></name><article-title>Novor: Real-Time
Peptide de Novo Sequencing Software</article-title>. <source>J. Am.
Soc. Mass Spectrom.</source><year>2015</year>, <volume>26</volume> (<issue>11</issue>), <fpage>1885</fpage>–<lpage>1894</lpage>. <pub-id pub-id-type="doi">10.1007/s13361-015-1204-0</pub-id>.<pub-id pub-id-type="pmid">26122521</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Tran</surname><given-names>N. H.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Xin</surname><given-names>L.</given-names></name>; <name><surname>Shan</surname><given-names>B.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name><article-title>De Novo Peptide
Sequencing by Deep Learning</article-title>. <source>Proc. Natl. Acad.
Sci. U. S. A.</source><year>2017</year>, <volume>114</volume> (<issue>31</issue>), <fpage>8247</fpage>–<lpage>8252</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1705691114</pub-id>.<pub-id pub-id-type="pmid">28720701</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Chi</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>He</surname><given-names>K.</given-names></name>; <name><surname>Wu</surname><given-names>L.</given-names></name>; <name><surname>Yang</surname><given-names>B.</given-names></name>; <name><surname>Sun</surname><given-names>R.-X.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Zeng</surname><given-names>W.-F.</given-names></name>; <name><surname>Song</surname><given-names>C.-Q.</given-names></name>; <name><surname>He</surname><given-names>S.-M.</given-names></name>; <name><surname>Dong</surname><given-names>M.-Q.</given-names></name><article-title>pNovo+: De Novo
Peptide Sequencing
Using Complementary HCD and ETD Tandem Mass Spectra</article-title>. <source>J. Proteome Res.</source><year>2013</year>, <volume>12</volume> (<issue>2</issue>), <fpage>615</fpage>–<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1021/pr3006843</pub-id>.<pub-id pub-id-type="pmid">23272783</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Chi</surname><given-names>H.</given-names></name>; <name><surname>Sun</surname><given-names>R.-X.</given-names></name>; <name><surname>Yang</surname><given-names>B.</given-names></name>; <name><surname>Song</surname><given-names>C.-Q.</given-names></name>; <name><surname>Wang</surname><given-names>L.-H.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Fu</surname><given-names>Y.</given-names></name>; <name><surname>Yuan</surname><given-names>Z.-F.</given-names></name>; <name><surname>Wang</surname><given-names>H.-P.</given-names></name>; <name><surname>He</surname><given-names>S.-M.</given-names></name>; <name><surname>Dong</surname><given-names>M.-Q.</given-names></name><article-title>pNovo: <italic>De Novo</italic> Peptide Sequencing
and Identification Using HCD Spectra</article-title>. <source>J. Proteome
Res.</source><year>2010</year>, <volume>9</volume> (<issue>5</issue>), <fpage>2713</fpage>–<lpage>2724</lpage>. <pub-id pub-id-type="doi">10.1021/pr100182k</pub-id>.<pub-id pub-id-type="pmid">20329752</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Chi</surname><given-names>H.</given-names></name>; <name><surname>Zhou</surname><given-names>W.-J.</given-names></name>; <name><surname>Zeng</surname><given-names>W.-F.</given-names></name>; <name><surname>He</surname><given-names>K.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Sun</surname><given-names>R.-X.</given-names></name>; <name><surname>He</surname><given-names>S.-M.</given-names></name><article-title>Open-pNovo: De Novo Peptide Sequencing
with Thousands of Protein Modifications</article-title>. <source>J.
Proteome Res.</source><year>2017</year>, <volume>16</volume> (<issue>2</issue>), <fpage>645</fpage>–<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00716</pub-id>.<pub-id pub-id-type="pmid">28019094</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="journal" id="cit39"><name><surname>Needleman</surname><given-names>S. B.</given-names></name>; <name><surname>Wunsch</surname><given-names>C. D.</given-names></name><article-title>A General Method Applicable to the
Search for Similarities
in the Amino Acid Sequence of Two Proteins</article-title>. <source>J. Mol. Biol.</source><year>1970</year>, <volume>48</volume> (<issue>3</issue>), <fpage>443</fpage>–<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1016/0022-2836(70)90057-4</pub-id>.<pub-id pub-id-type="pmid">5420325</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Smith</surname><given-names>T. F.</given-names></name>; <name><surname>Waterman</surname><given-names>M. S.</given-names></name><article-title>Comparison of Biosequences</article-title>. <source>Adv.
Appl. Math</source><year>1981</year>, <volume>2</volume> (<issue>4</issue>), <fpage>482</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1016/0196-8858(81)90046-4</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Henikoff</surname><given-names>S.</given-names></name>; <name><surname>Henikoff</surname><given-names>J. G.</given-names></name><article-title>Amino Acid Substitution Matrices
from Protein Blocks</article-title>. <source>Proc. Natl. Acad. Sci.
U. S. A.</source><year>1992</year>, <volume>89</volume> (<issue>22</issue>), <fpage>10915</fpage>–<lpage>10919</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.89.22.10915</pub-id>.<pub-id pub-id-type="pmid">1438297</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="journal" id="cit42"><name><surname>Johnson</surname><given-names>R. S.</given-names></name>; <name><surname>Martin</surname><given-names>S. A.</given-names></name>; <name><surname>Biemann</surname><given-names>K.</given-names></name><article-title>Collision-Induced Fragmentation
of
(M + H)+ Ions of Peptides. Side Chain Specific Sequence Ions</article-title>. <source>Int. J. Mass Spectrom Ion Process</source><year>1988</year>, <volume>86</volume>, <fpage>137</fpage>–<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/0168-1176(88)80060-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Bouwmeester</surname><given-names>R.</given-names></name>; <name><surname>Gabriels</surname><given-names>R.</given-names></name>; <name><surname>Hulstaert</surname><given-names>N.</given-names></name>; <name><surname>Martens</surname><given-names>L.</given-names></name>; <name><surname>Degroeve</surname><given-names>S.</given-names></name><article-title>DeepLC Can
Predict Retention Times for Peptides That Carry As-yet Unseen Modifications</article-title>. <source>Nat. Methods</source><year>2021</year>, <volume>18</volume> (<issue>11</issue>), <fpage>1363</fpage>–<lpage>1369</lpage>. <pub-id pub-id-type="doi">10.1038/s41592-021-01301-5</pub-id>.<pub-id pub-id-type="pmid">34711972</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="journal" id="cit44"><name><surname>Sinitcyn</surname><given-names>P.</given-names></name>; <name><surname>Hamzeiy</surname><given-names>H.</given-names></name>; <name><surname>Salinas
Soto</surname><given-names>F.</given-names></name>; <name><surname>Itzhak</surname><given-names>D.</given-names></name>; <name><surname>McCarthy</surname><given-names>F.</given-names></name>; <name><surname>Wichmann</surname><given-names>C.</given-names></name>; <name><surname>Steger</surname><given-names>M.</given-names></name>; <name><surname>Ohmayer</surname><given-names>U.</given-names></name>; <name><surname>Distler</surname><given-names>U.</given-names></name>; <name><surname>Kaspar-Schoenefeld</surname><given-names>S.</given-names></name>; <name><surname>Prianichnikov</surname><given-names>N.</given-names></name>; <name><surname>Yılmaz</surname><given-names>Ş.</given-names></name>; <name><surname>Rudolph</surname><given-names>J. D.</given-names></name>; <name><surname>Tenzer</surname><given-names>S.</given-names></name>; <name><surname>Perez-Riverol</surname><given-names>Y.</given-names></name>; <name><surname>Nagaraj</surname><given-names>N.</given-names></name>; <name><surname>Humphrey</surname><given-names>S. J.</given-names></name>; <name><surname>Cox</surname><given-names>J.</given-names></name><article-title>MaxDIA Enables
Library-Based
and Library-Free Data-Independent Acquisition Proteomics</article-title>. <source>Nat. Biotechnol.</source><year>2021</year>, <volume>39</volume> (<issue>12</issue>), <fpage>1563</fpage>–<lpage>1573</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-021-00968-7</pub-id>.<pub-id pub-id-type="pmid">34239088</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Proteome Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Proteome Res</journal-id>
    <journal-id journal-id-type="publisher-id">pr</journal-id>
    <journal-id journal-id-type="coden">jprobs</journal-id>
    <journal-title-group>
      <journal-title>Journal of Proteome Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1535-3893</issn>
    <issn pub-type="epub">1535-3907</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11301774</article-id>
    <article-id pub-id-type="pmid">38932690</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jproteome.4c00188</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>A Handle on Mass
Coincidence Errors in <italic>De
Novo</italic> Sequencing of Antibodies by Bottom-up Proteomics</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0594-0993</contrib-id>
        <name>
          <surname>Schulte</surname>
          <given-names>Douwe</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9310-8226</contrib-id>
        <name>
          <surname>Snijder</surname>
          <given-names>Joost</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
      </contrib>
      <aff id="aff1">Biomolecular Mass Spectrometry
and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht
Institute of Pharmaceutical Sciences, <institution>Utrecht
University</institution>, Padualaan 8, Utrecht 3584
CH, <country>The Netherlands</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>j.snijder@uu.nl</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>27</day>
      <month>06</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>02</day>
      <month>08</month>
      <year>2024</year>
    </pub-date>
    <volume>23</volume>
    <issue>8</issue>
    <fpage>3552</fpage>
    <lpage>3559</lpage>
    <history>
      <date date-type="received">
        <day>11</day>
        <month>03</month>
        <year>2024</year>
      </date>
      <date date-type="accepted">
        <day>20</day>
        <month>06</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>29</day>
        <month>05</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2024 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2024</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0006" id="ab-tgr1"/>
      </p>
      <p>Antibody sequences
can be determined at 99% accuracy directly from
the polypeptide product by using bottom-up proteomics techniques.
Sequencing accuracy at the peptide level is limited by the isobaric
residues leucine and isoleucine, incomplete fragmentation spectra
in which the order of two or more residues remains ambiguous due to
lacking fragment ions for the intermediate positions, and isobaric
combinations of amino acids, of potentially different lengths, for
example, GG = N and GA = Q. Here, we present several updates to Stitch
(v1.5), which performs template-based assembly of <italic>de novo</italic> peptides to reconstruct antibody sequences. This version introduces
a mass-based alignment algorithm that explicitly accounts for mass
coincidence errors. In addition, it incorporates a postprocessing
procedure to assign I/L residues based on secondary fragments (satellite
ions, <italic>i.e.</italic>, <italic>w-</italic>ions). Moreover, evidence
for sequence assignments can now be directly evaluated with the addition
of an integrated spectrum viewer. Lastly, input data from a wider
selection of <italic>de novo</italic> peptide sequencing algorithms
are allowed, now including Casanovo, PEAKS, Novor.Cloud, pNovo, and
MaxNovo, in addition to flat text and FASTA. Combined, these changes
make Stitch compatible with a larger range of data processing pipelines
and improve its tolerance to peptide-level sequencing errors.</p>
    </abstract>
    <kwd-group>
      <kwd>mass spectrometry</kwd>
      <kwd><italic>de novo</italic> sequencing</kwd>
      <kwd>sequence assembly</kwd>
      <kwd>antibodies</kwd>
      <kwd>alignment</kwd>
      <kwd>isobaric</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>HORIZON EUROPE European Research Council</institution>
            <institution-id institution-id-type="doi">10.13039/100019180</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>101077640</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Exacte en Natuurwetenschappen</institution>
            <institution-id institution-id-type="doi">10.13039/501100024870</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>024.002.009</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>pr4c00188</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>pr4c00188</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Antibodies are essential components of
the adaptive immune system
that can recognize a vast array of antigens in the fight against pathogens
or in autoimmune disease.<sup><xref ref-type="bibr" rid="ref1">1</xref>−<xref ref-type="bibr" rid="ref4">4</xref></sup> The diversity of antigens recognized by antibodies
is mirrored by the diversity of the antibody sequences. This diversity
is generated by somatic recombination and hypermutation of the paired
heavy and light chains, taking place in singular B cells. Studying
these unique antibody sequences therefore is crucial to understanding
the immune response in health and disease and to developing diagnostics,
therapeutics, and affinity reagents for life science research based
on antibody-mediated recognition and binding of target antigens.</p>
    <p>Established methods for antibody sequencing target the coding mRNA
in single B cells.<sup><xref ref-type="bibr" rid="ref5">5</xref>−<xref ref-type="bibr" rid="ref12">12</xref></sup> While these methods have laid the foundation for our current understanding
of the antibody response, they do not directly access the functional
secreted products found in bodily fluids in the same way as they are
probed in common serological assays (to determine the binding and
neutralization titers following natural infection or immunization).
Additionally, B cells reside in the spleen, bone marrow, and blood,
of which only the latter population can be easily sampled in human
subjects. In contrast, mass spectrometry-based methods can probe specific
antibody sequences directly from the secreted polypeptide product,
thereby circumventing the need to sample the antibody-producing B-cell
clone and providing a direct glimpse into the so-called serum compartment
of the immunoglobulin repertoire.<sup><xref ref-type="bibr" rid="ref13">13</xref>−<xref ref-type="bibr" rid="ref26">26</xref></sup></p>
    <p>Using a bottom-up proteomics approach, accurate peptide sequences
can be determined and assembled into complete heavy- and light-chain
sequences. We have recently developed the software tool Stitch to
perform template-based assembly of peptide sequences against the coding
gene segments of antibodies available in immunogenetics databases.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Stitch has been shown to enable the accurate
reconstruction of monoclonal antibody sequences, as well as the sequencing
of isolated Fab fragments from patient serum, M-proteins in monoclonal
gammopathies, antibody light chains from urine, and the profiling
of whole IgG from COVID-19 patient sera.<sup><xref ref-type="bibr" rid="ref13">13</xref>−<xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup> Sequence accuracies of ∼99% can be obtained,
which is sufficient to reverse engineer functional antibody products.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> Remaining sequencing errors stem in large parts from common mass
coincidences of isobaric residues like leucine/isoleucine but also
from incomplete fragmentation spectra in which the order of two or
more residues remains ambiguous due to lacking fragment ions for the
intermediate positions. Likewise, different combinations of amino
acids, of potentially different lengths, can also coincide to the
same mass (e.g., GG=N, GA=Q). In addition to limiting
the accuracy of the input peptide sequences, these mass coincidence
errors may also hamper proper assembly of the short peptides against
the antibody template sequences.</p>
    <p>Here, we discuss several recent
updates to Stitch (v1.1 up to and
including v1.5) in light of common MS-based <italic>de novo</italic> sequencing errors. These updates include a mass-based alignment
algorithm (akin to Meta-SPS-contig<sup><xref ref-type="bibr" rid="ref30">30</xref></sup>),
a post-processing procedure to assign I/L residues based on secondary
fragments, a built-in spectrum viewer, a graph-based analysis that
tracks the connectivity between identified sequence variants, and
the ability to use a wider selection of <italic>de novo</italic> peptide
sequencing programs as input, including Casanovo, MaxNovo, Novor.Cloud,
PEAKS, and pNovo.<sup><xref ref-type="bibr" rid="ref31">31</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> Combined, these changes make Stitch compatible with a larger range
of data processing pipelines and improve its tolerance to peptide-level
sequencing errors.</p>
  </sec>
  <sec id="sec2">
    <title>Methods</title>
    <sec id="sec2.1">
      <title>Mass Coincidence Rate</title>
      <p>The mass coincidence rates over
different precisions and mass ranges (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A,B) were calculated by generating all possible
amino acid sequences from the canonical amino acids for each mass
range (without rotations), including the following modifications:
Carbamidomethyl (fixed on C), Oxidation (variable on WHM), Deamidated
(variable on NQ), Glu → pyro-Glu (variable on N-term E), and
Gln → pyro-Glu (variable on N-term Q). For each of these sets
of possible sequences, the number of unique masses was calculated
by going through the possible sets sorted on mass and greedily combining
any set with the previous if within the given precision.</p>
    </sec>
    <sec id="sec2.2">
      <title>Smith-Waterman
Comparison to Mass-Based Alignment</title>
      <p>The
comparison between Smith–Waterman alignment (SWA) and mass-based
alignment (MBA) (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A) was made by running Stitch with different PEAKS ALC peptide cutoff
scores. The other parameters used were enforce unique 0.9, cutoff
score template matching 5, cutoff score recombination 5, with the
default templates for <italic>Homo sapiens</italic> heavy
and light chains, and common contaminants. The identity was determined
using a version of MBA by comparing the consensus sequence as given
by these runs to the known sequence. The coverage was determined by
counting the fractions of positions that had at least one peptide
matching as given in the Stitch FASTA export.</p>
      <p>The average scores
for each ALC bin (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B) were calculated using the Herceptin data at PEAKS ALC cutoff
50 from <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A.
The score was normalized by dividing the absolute score by the length
of each peptide it matched on the template. These scores were grouped
by ALC of the peptide, and the average and standard deviation were
calculated.</p>
    </sec>
    <sec id="sec2.3">
      <title>Accuracy/Error Estimates</title>
      <p>The likelihood
of a given
number of mistakes (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>) was calculated following a simple binomial model, in which
the probability <italic>P</italic>(<italic>C</italic>, <italic>T</italic>) of obtaining <italic>C</italic> correct amino acids in a sequence
of length <italic>T,</italic> with a given accuracy <italic>a</italic>, equals <italic>a</italic><sup><italic>C</italic></sup> × (1
– <italic>a</italic>)<sup><italic>T</italic>−<italic>C</italic></sup>, which can be simplified to <italic>a</italic><sup><italic>T</italic></sup> when <italic>C</italic> equals <italic>T</italic>, meaning no mistakes are made, which can then be solved for <italic>a</italic> as <inline-formula id="d34e285"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_m001.gif"/></inline-formula>.</p>
    </sec>
    <sec id="sec2.4">
      <title>Accuracy
of I/L Assignments</title>
      <p>The accuracy at I/L positions
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B) was determined
by running Stitch with the same data as the SWA vs MBA comparison,
with PEAKS cutoff ALC 95, enforce unique 0.9, template matching and
recombine cutoff score 10, mass-based alignment, the default templates
for <italic>Homo sapiens</italic> heavy and light chain,
and common contaminants, the raw data, and by turning on XleDisambiguation
on the input file. For each I/L location, the known true sequence,
Stitch outcome, and germline sequence were compared.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Results</title>
    <p>Stitch assembles peptides from <italic>de novo</italic> sequencing
programs for bottom-up LC-MS/MS data in the correct framework of the
heavy and light chains of an antibody. An outline of the assembly
and processing performed by Stitch, including the new features described
here, is presented in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. The previously published version of Stitch was already able
to handle PEAKS, FASTA, and plain text data, which is now extended
to include the output from Casanovo, MaxNovo, Novor.Cloud, and pNovo.<sup><xref ref-type="bibr" rid="ref31">31</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> These peptides are aligned to the germline sequences of the corresponding
gene segments (V/J/C) for the appropriate species and placed when
the alignment score exceeds a user-defined cutoff. The consensus sequence
for a single template is made from all placed peptides, weighed for
the confidence and abundance of the individually placed peptides as
reported by the peptide <italic>de novo</italic> sequencing programs.
This procedure robustly places peptide reads in the correct framework
of the full antibody sequence except for the hypervariable Complementarity
Determining Region 3 of the heavy chain (CDRH3). CDRH3 is formed by
the junction of three coding gene segments V, D, and J, of which D
is exceptionally short and variable, such that germline sequences
do not provide a functional template to guide the assembly. Instead,
Stitch extends the flanking V- and J-segments with a user-defined
number of wildcard “X” characters, such that overhanging
reads from the V- and J-segments can be used to extend the consensus
sequence into the CDRH3 region. The resulting overhanging V- and J-sequences
are then aligned to find the overlap from both sides to reconstruct
CDRH3. In contrast, CDR3 of the light chain is encoded only with V-
and J-segments and can typically be reconstructed from the first-order
template matching step alone. These consensus sequences of the recombined
V- and J-segments are then used for a second template matching step
to reconstruct the final consensus sequence of the antibody. It should
be noted that this procedure is only suitable for monoclonal antibodies
(although it is tolerant to a moderate background of polyclonal sequences).<sup><xref ref-type="bibr" rid="ref13">13</xref>−<xref ref-type="bibr" rid="ref15">15</xref></sup> The reconstruction of CDRH3 from disperse polyclonal mixtures currently
requires manual curation of the candidate sequences. The template-based
assembly (and recombination) results of Stitch are written out as
an interactive report where all peptide alignments can be inspected,
and overview statistics like total score/area are collected for every
template sequence. To aid in the analysis of disperse polyclonal mixtures,
this new version of Stitch introduces the so-called “variant
graph”, which shows how co-occurring sequence variations in
reference to the templates are connected by peptide reads.</p>
    <fig id="fig1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Overview of
the program Stitch.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0001" id="gr1" position="float"/>
    </fig>
    <p>We also introduced a
fundamentally different alignment algorithm
for the placement of input reads against template sequences. We previously
used a modified version of the Smith–Waterman algorithm (SWA)
using a matrix based on BLOSUM62.<sup><xref ref-type="bibr" rid="ref39">39</xref>−<xref ref-type="bibr" rid="ref41">41</xref></sup> The SWA only accounts
for mismatches between input reads and template sequences that stem
from evolutionary processes like somatic hypermutation observed in
mature antibody sequences compared to the germline precursors. In
our experimental data, however, these mismatches are further convoluted,
with errors inherent to an MS-based approach to peptide sequencing.</p>
    <p>To illustrate the sequencing errors that MS is prone to, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A plots the residue masses of the 20 common amino acids (with
common modifications) on a scale of 50 to 200 Da, also including the
amino acid combinations that fall within this range. Considering that
mass analyzers in current proteomics setups typically operate within
a precision range of 0.01–0.50 Da, we can broadly distinguish
between four categories of MS-based sequencing errors. The first category
is the isobaric residues isoleucine and leucine, which simply have
identical masses and cannot be distinguished without the presence
of secondary fragment ions (as further discussed below). The second
category of common MS-based errors includes larger isobaric <italic>sets</italic> of amino acids, where different combinations of residues
amount to identical masses and cannot be distinguished. This second
category stems from missing fragment ions in the MS/MS spectra. There
are three subcategories of errors in this second category: (a) simple
rotations within a set (e.g., AS = SA), b) isobaric sets (e.g., AS
= GT), and (c) isobaric sets of different lengths (e.g., N = GG, Q
= GA). For sets of three residues or more, combinations of these subcategories
may occur. The third category of common MS-based errors includes (modified)
residues that are not strictly identical in mass but are so similar
that they cannot be distinguished, given the experimental precision
limits of the mass analyzer. For instance, the mass difference between
K and Q is 0.036 Da, between M<sup>ox</sup> and F 0.033 Da. This third
category of MS-based errors can be eliminated with the use of a high-precision
mass analyzer (TOF, FT-MS), but it poses a significant limitation
to <italic>de novo</italic> sequencing at lower precision (ion trap).
The fourth category of common MS-based errors does not necessarily
stem from analytical limitations but rather from artifacts of the
sample processing pipeline in the form of deamidation of Q and especially
N, converting these residues to E and D, respectively.</p>
    <fig id="fig2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Mass coincidence errors
in de novo peptide sequencing. (A) All
possible amino acid sequences up to 200 Da, including common modifications
(carbamidomethyl fixed on C, pyro-Glu, deamidation on N and Q, and
oxidation on M and H). (B) The fraction of sequences that can be told
apart (specificity) is based on the precision in Da and the upper
mass limit (not counting rotations). (C) Illustration of how the mass-based
alignment provides a better handle on mass coincidence errors.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0002" id="gr2" position="float"/>
    </fig>
    <p><xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B illustrates
how these common MS-based errors accumulate as a function of precision
for progressively larger mass intervals (i.e., a higher number of
missing fragments). A few obvious but fundamental requirements and
limitations for <italic>de novo</italic> peptide sequencing can be
observed from this “survival” analysis, showing what
fraction of possible unique residues (or residue combinations) can
be distinguished based on their mass, not counting rotations. First,
it is of the utmost importance to achieve complete fragmentation as
category 2 errors (isobaric subsets) readily accumulate over larger
mass intervals. Second, category 3 errors (similar residue masses)
can be eliminated with high precision mass analyzers. Important to
note is that the required precision to eliminate category 3 errors
is readily achieved on modern mass analyzers for small peptide fragments
with low charge states but that this becomes a significant limitation
for larger fragments with higher charge states in middle- and top-down
approaches. Considering these common MS-based errors, we propose here
a modification of the SWA to perform the template-based assembly for
antibody sequencing.</p>
    <p>One of the most important drawbacks in
the context of these MS-based
errors is that in SWA, a substitution can only be a single amino acid
to another single amino acid while the category 2 errors affect multiple
consecutive residues. The new mass-based alignment we devised considers
these errors by aligning not only single amino acids but also larger
sets, illustrated in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C. It does this by supplementing the alignment steps looked
for in SWA (i.e., match/mismatch/insertion/deletion), with two additional
steps: rotation and isobaric. These last two steps can be of length
up to <italic>N</italic> steps on both the template and peptide (e.g.,
match 2 amino acids on the template with 3 on the input peptide).
With this addition, the category 2 errors, up to N amino acids, can
easily be found. The score for each aligned set of amino acids is
looked up in a premade two-dimensional array with the same modified
BLOSUM62 base matrix in the top left and all category 2 errors given
a nonzero score in the array based on their mass identity. It is important
for the behavior of the alignment that these rotations and isobaric
matches score lower than any direct match. Hence, rotations score
3 per amino acid involved and isobaric matches score 2 per the maximum
number of amino acids involved. The alignment algorithm looks for
any nonzero score in the set of steps of up to <italic>N</italic> residues,
alongside the normal cases for SWA, and the highest scoring of the
possible steps is chosen. This approach is similar to Meta-SPS contig,
with the main difference that alignment and assembly is performed
on the level of the output peptide sequences, rather than the MS/MS
data itself.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup></p>
    <p>Use of the mass-based
alignment (MBA) versus SWA improves the tolerance
to mass coincidence errors during template-based assembly. This difference
is illustrated in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> using PEAKS input data for the two monoclonal antibodies
Herceptin and F59. PEAKS provides a peptide-level average local confidence
(ALC) score between 0 and 99, where peptides with a lower ALC typically
miss more fragment ions to support the given sequence. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A shows how the average length-normalized alignment score
during the assembly develops as a function of the ALC cutoff for MBA
vs SWA. By design, the alignment scores are consistently higher using
MBA vs SWA, the margin illustrating just how common mass coincidence
errors are in the input data. The higher degrees of freedom in MBA
evidently allow for better placement of the input reads, while we
see no signs of overfitting, even at the relatively low alignment
score cutoff of 5 used in this analysis. Peptides with higher ALC
(and fewer errors) yield higher alignment scores, as expected, but
to achieve optimal accuracy in the final consensus sequences, there
is an important trade-off to be made between selection of the highest-scoring
input reads and achieving optimal coverage. As the coverage plummets
with ALC cutoff scores &gt;95, it follows that a substantial tolerance
to mass coincidence errors is required to assemble the complete sequences
(given the limitations of the experimental input data) by including
lower ALC (&lt;95) peptides (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). Of note, SWA cannot align any peptides below ALC
55, while these may still be placed using MBA.</p>
    <fig id="fig3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Mass-based alignment
results. (A) Average normalized score (score/alignment
length) as a function of PEAKS ALC. Note that the missing points for
CutoffALC &lt; 55 for Smith–Waterman alignment is because no
peptides with these scores could be placed by this alignment algorithm.
(B) Result of running Stitch with the Herceptin and F59 sample data
with different read cutoff scores presented as accuracy, defined here
as identity against the true sequence, in a solid line, and coverage,
the fraction of positions covered by at least one peptide, drawn in
a dotted line. Note that the results were generated running Stitch
with a low cutoff score for template matching. (C) An excerpt of the
alignment of the highest scoring light chain variable gene from the
Stitch report for Herceptin using mass-based alignment and CutoffALC
85.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0003" id="gr3" position="float"/>
    </fig>
    <p>The accuracy of the final consensus
sequences of Herceptin and
F59 is plotted as a function of ALC cutoff in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B, illustrating that MBA outperforms SWA
across the sampled range. The accuracy increases from 0.95 (SWA) to
0.99 (MBA). While this may seem like a moderate increase at first,
it represents a better than 100-fold improvement in the probability
to determine the sequence of a 120 amino acid long variable domain
with zero mistakes (<italic>P</italic> = 0.002 for accuracy 0.95 vs <italic>P</italic> = 0.299 for accuracy 0.99). Of note, to achieve a probability
of <italic>P</italic> &gt; 0.99 to make zero mistakes in a sequence
of
this length, the accuracy needs to further improve to &gt;0.9999 (see <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>).</p>
    <fig id="fig4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Probability of the indicated number of errors in a sequence of
120 amino acids given the sequencing accuracy per amino acid.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0004" id="gr4" position="float"/>
    </fig>
    <p>In addition to the new MBA, Stitch is also updated
to read and
display fragmentation spectra in an interactive spectrum viewer (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A). This allows the user to manually inspect the underlying
data for an assigned sequence. Moreover, accessing the fragmentation
spectra in Stitch also allowed us to implement a new postprocessing
procedure to differentiate between leucine/isoleucine based on secondary
fragment ions that can be observed in some fragmentation modes, notably
electron transfer high energy collision dissociation data.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> These diagnostic satellite ions (known as <italic>w</italic>/<italic>d</italic>-ions) are formed by secondary fragmentation
of <italic>z-</italic> and <italic>a-</italic>ions, by transfer of
the free electron to the side chain, and breaking of a bond to the
first C atom in the side chain (Cβ). As the side chains are
different between isoleucine and leucine, the possible mass shifts
of the satellite ions are different, being 15 and 29 Da for isoleucine
(loss of C<sub>1</sub>H<sub>3</sub> and C<sub>2</sub>H<sub>5</sub>) and 43 Da for leucine (loss of C<sub>3</sub>H<sub>7</sub>). Stitch
gives the option to use these satellite ions to find the most likely
candidate for each I/L position. This improves the fraction of correctly
identified I/L positions from 0.81 (when defaulting to the germline
template sequence or to L in the case of newly introduced I/L mutations)
to 0.94 when using the satellite ions, as seen in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B.</p>
    <fig id="fig5" position="float">
      <label>Figure 5</label>
      <caption>
        <p>Satellite ion usage to
identify I/L. (A) Screenshot from the spectrum
viewer of a CDRH3 peptide of Herceptin. (B) The fraction of correct
I/L identifications using just the germline (previous version of Stitch)
or the new satellite ions; alignment identity is used as measure of
accuracy. (C) An example spectrum with satellite ions annotated as
Stitch would display it.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_0005" id="gr5" position="float"/>
    </fig>
  </sec>
  <sec id="sec4">
    <title>Discussion</title>
    <p>These
recent updates to Stitch provide a better handle on mass
coincidence errors for <italic>de novo</italic> antibody sequencing
by LC-MS/MS. These improvements extend to any MS-based <italic>de
novo</italic> sequencing application beyond antibodies, and indeed,
Stitch can perform the same tasks on an arbitrary set of template
sequences.</p>
    <p>Implementation of the mass-based alignment shed light
on fundamental
requirements and limitations for MS-based <italic>de novo</italic> sequencing and set out some important goals for the near future.
To minimize peptide-level sequencing errors, it is crucially important
to analyze at a precision of at least 0.02 Da, achieve complete fragmentation,
and obtain secondary fragment ions to differentiate I/L. The latter
two points call for use of complementary fragmentation techniques
beyond CID. Currently, accuracies of 0.99 can be achieved on the consensus
sequence level, but to achieve a milestone 99% confidence in error-free
sequences, this needs to improve to &gt;0.9999 for the case of an
antibody
variable domain of 120 amino acids. Based on our own work, this requires
further improvement of I/L assignments, but even more so elimination
of deamidation errors (primarily N/D) from the sample processing workflows.
Moreover, the 0.99 accuracy is currently based on consensus sequences
from overlapping peptides, and as we expand applications to complex
polyclonal antibody mixtures, the depth of coverage will inevitably
suffer, again calling for improved fragmentation to minimize sequencing
errors at the peptide level. In addition to improved fragmentation,
recent improvements in retention time prediction may also be leveraged
in <italic>de novo</italic> peptide sequencing algorithms to improve
peptide-level sequence accuracy.<sup><xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup></p>
    <p>Stitch
is now compatible with a wide range of current de novo sequencing
algorithms, providing an improved strategy for sequence assembly with
mass-based alignment and the opportunity to browse spectrum-level
evidence for the determined sequence to aid in manual curation. It
is a versatile tool for MS-based antibody sequencing and beyond and
may provide a springboard to dive into the serum compartment of the
antibody repertoire with proteomics techniques.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes1">
    <title>Data Availability Statement</title>
    <p>The source code
of Stitch is available on GitHub: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/snijderlab/stitch">https://github.com/snijderlab/stitch</uri>. All Stitch HTML results related to this study are provided as Supporting
Data. The raw data of the monoclonal antibodies Herceptin and F59
are available under identifier PXD023419 and doi 10.6084/m9.figshare.13194005,
respectively.</p>
  </notes>
  <notes id="notes2" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00188?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00188</ext-link>.<list id="silist" list-type="simple"><list-item><p>Isobaric statistics;
mass-based benchmark, and xln disambiguation
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.4c00188/suppl_file/pr4c00188_si_001.zip">ZIP</ext-link>)</p></list-item><list-item><p>All
Stitch HTML results related to this study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.4c00188/suppl_file/pr4c00188_si_002.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_si_001.zip">
        <caption>
          <p>pr4c00188_si_001.zip</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr4c00188_si_002.pdf">
        <caption>
          <p>pr4c00188_si_002.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d14e516-autogenerated">
    <p>The authors declare no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>The authors thank Bastiaan
de Graaf for the fruitful
discussions regarding the design of Stitch and the mass-based alignment
algorithm. We would also like to thank Lukas Käll for helpful
input and feedback on the manuscript. This research was funded by
the Dutch Research Council NWO Gravitation 2013 BOO, Institute for
Chemical Immunology (ICI; 024.002.009), and the European Research
Council Executive Agency HORIZON ERC-2022-STG (FLAVIR; 101077640).</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Casadevall</surname><given-names>A.</given-names></name>; <name><surname>Pirofski</surname><given-names>L.</given-names></name><article-title>A New Synthesis for
Antibody-Mediated Immunity</article-title>. <source>Nat. Immunol</source><year>2012</year>, <volume>13</volume> (<issue>1</issue>), <fpage>21</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2184</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Davies</surname><given-names>D. R.</given-names></name>; <name><surname>Metzger</surname><given-names>H.</given-names></name><article-title>Structural Basis of
Antibody Function</article-title>. <source>Annu. Rev. Immunol.</source><year>1983</year>, <volume>1</volume> (<issue>1</issue>), <fpage>87</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.iy.01.040183.000511</pub-id>.<pub-id pub-id-type="pmid">6399980</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Lleo</surname><given-names>A.</given-names></name>; <name><surname>Invernizzi</surname><given-names>P.</given-names></name>; <name><surname>Gao</surname><given-names>B.</given-names></name>; <name><surname>Podda</surname><given-names>M.</given-names></name>; <name><surname>Gershwin</surname><given-names>M. E.</given-names></name><article-title>Definition
of Human Autoimmunity — Autoantibodies versus Autoimmune Disease</article-title>. <source>Autoimmun Rev.</source><year>2010</year>, <volume>9</volume> (<issue>5</issue>), <fpage>A259</fpage>–<lpage>A266</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2009.12.002</pub-id>.<pub-id pub-id-type="pmid">19963079</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Naparstek</surname><given-names>Y.</given-names></name>; <name><surname>Plotz</surname><given-names>P. H.</given-names></name><article-title>The Role of Autoantibodies
in Autoimmune Disease</article-title>. <source>Annu. Rev. Immunol.</source><year>1993</year>, <volume>11</volume> (<issue>1</issue>), <fpage>79</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.iy.11.040193.000455</pub-id>.<pub-id pub-id-type="pmid">8476578</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Avram</surname><given-names>O.</given-names></name>; <name><surname>Kigel</surname><given-names>A.</given-names></name>; <name><surname>Vaisman-Mentesh</surname><given-names>A.</given-names></name>; <name><surname>Kligsberg</surname><given-names>S.</given-names></name>; <name><surname>Rosenstein</surname><given-names>S.</given-names></name>; <name><surname>Dror</surname><given-names>Y.</given-names></name>; <name><surname>Pupko</surname><given-names>T.</given-names></name>; <name><surname>Wine</surname><given-names>Y.</given-names></name><article-title>PASA: Proteomic
Analysis of Serum Antibodies Web Server</article-title>. <source>PLoS
Comput. Biol.</source><year>2021</year>, <volume>17</volume> (<issue>1</issue>), <elocation-id>e1008607</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008607</pub-id>.<pub-id pub-id-type="pmid">33493161</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Lavinder</surname><given-names>J. J.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name><article-title>Next-Generation
Sequencing and Protein Mass Spectrometry for the Comprehensive Analysis
of Human Cellular and Serum Antibody Repertoires</article-title>. <source>Curr. Opin Chem. Biol.</source><year>2015</year>, <volume>24</volume>, <fpage>112</fpage>–<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2014.11.007</pub-id>.<pub-id pub-id-type="pmid">25461729</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Chromikova</surname><given-names>V.</given-names></name>; <name><surname>Joyce</surname><given-names>M. G.</given-names></name>; <name><surname>Vollmers</surname><given-names>C.</given-names></name>; <name><surname>Leung</surname><given-names>K.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>DeKosky</surname><given-names>B. J.</given-names></name>; <name><surname>Lee</surname><given-names>C.-H.</given-names></name>; <name><surname>Lavinder</surname><given-names>J. J.</given-names></name>; <name><surname>Murrin</surname><given-names>E. M.</given-names></name>; <name><surname>Chrysostomou</surname><given-names>C.</given-names></name>; <name><surname>Hoi</surname><given-names>K. H.</given-names></name>; <name><surname>Tsybovsky</surname><given-names>Y.</given-names></name>; <name><surname>Thomas</surname><given-names>P. V.</given-names></name>; <name><surname>Druz</surname><given-names>A.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Kong</surname><given-names>W.-P.</given-names></name>; <name><surname>Park</surname><given-names>D.</given-names></name>; <name><surname>Popova</surname><given-names>L. I.</given-names></name>; <name><surname>Dekker</surname><given-names>C. L.</given-names></name>; <name><surname>Davis</surname><given-names>M. M.</given-names></name>; <name><surname>Carter</surname><given-names>C. E.</given-names></name>; <name><surname>Ross</surname><given-names>T. M.</given-names></name>; <name><surname>Ellington</surname><given-names>A. D.</given-names></name>; <name><surname>Wilson</surname><given-names>P. C.</given-names></name>; <name><surname>Marcotte</surname><given-names>E. M.</given-names></name>; <name><surname>Mascola</surname><given-names>J. R.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name>; <name><surname>Krammer</surname><given-names>F.</given-names></name>; <name><surname>Quake</surname><given-names>S. R.</given-names></name>; <name><surname>Kwong</surname><given-names>P. D.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name><article-title>Molecular-Level
Analysis of the Serum Antibody Repertoire in Young Adults before and
after Seasonal Influenza Vaccination</article-title>. <source>Nat. Med.</source><year>2016</year>, <volume>22</volume> (<issue>12</issue>), <fpage>1456</fpage>–<lpage>1464</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4224</pub-id>.<pub-id pub-id-type="pmid">27820605</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Paparoditis</surname><given-names>P.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>Frühwirth</surname><given-names>A.</given-names></name>; <name><surname>McDaniel</surname><given-names>J. R.</given-names></name>; <name><surname>Jung</surname><given-names>J.</given-names></name>; <name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Hussein</surname><given-names>D. A.</given-names></name>; <name><surname>Tanno</surname><given-names>Y.</given-names></name>; <name><surname>Pappas</surname><given-names>L.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name>; <name><surname>Corti</surname><given-names>D.</given-names></name>; <name><surname>Lanzavecchia</surname><given-names>A.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name><article-title>Persistent Antibody Clonotypes Dominate
the Serum Response to Influenza over Multiple Years and Repeated Vaccinations</article-title>. <source>Cell Host Microb.</source><year>2019</year>, <volume>25</volume> (<issue>3</issue>), <fpage>367</fpage>–<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2019.01.010</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Lindesmith</surname><given-names>L. C.</given-names></name>; <name><surname>McDaniel</surname><given-names>J. R.</given-names></name>; <name><surname>Changela</surname><given-names>A.</given-names></name>; <name><surname>Verardi</surname><given-names>R.</given-names></name>; <name><surname>Kerr</surname><given-names>S. A.</given-names></name>; <name><surname>Costantini</surname><given-names>V.</given-names></name>; <name><surname>Brewer-Jensen</surname><given-names>P. D.</given-names></name>; <name><surname>Mallory</surname><given-names>M. L.</given-names></name>; <name><surname>Voss</surname><given-names>W. N.</given-names></name>; <name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Blazeck</surname><given-names>J. J.</given-names></name>; <name><surname>Ippolito</surname><given-names>G. C.</given-names></name>; <name><surname>Vinje</surname><given-names>J.</given-names></name>; <name><surname>Kwong</surname><given-names>P. D.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name>; <name><surname>Baric</surname><given-names>R. S.</given-names></name><article-title>Sera Antibody Repertoire
Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing
Responses after Human Norovirus Vaccination</article-title>. <source>Immunity</source><year>2019</year>, <volume>50</volume> (<issue>6</issue>), <fpage>1530</fpage>–<lpage>1541</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2019.05.007</pub-id>.<pub-id pub-id-type="pmid">31216462</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Boutz</surname><given-names>D. R.</given-names></name>; <name><surname>Horton</surname><given-names>A. P.</given-names></name>; <name><surname>Wine</surname><given-names>Y.</given-names></name>; <name><surname>Lavinder</surname><given-names>J. J.</given-names></name>; <name><surname>Georgiou</surname><given-names>G.</given-names></name>; <name><surname>Marcotte</surname><given-names>E. M.</given-names></name><article-title>Proteomic Identification of Monoclonal Antibodies from
Serum</article-title>. <source>Anal. Chem.</source><year>2014</year>, <volume>86</volume> (<issue>10</issue>), <fpage>4758</fpage>–<lpage>4766</lpage>. <pub-id pub-id-type="doi">10.1021/ac4037679</pub-id>.<pub-id pub-id-type="pmid">24684310</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Ellebrecht</surname><given-names>C. T.</given-names></name>; <name><surname>Mukherjee</surname><given-names>E. M.</given-names></name>; <name><surname>Zheng</surname><given-names>Q.</given-names></name>; <name><surname>Choi</surname><given-names>E. J.</given-names></name>; <name><surname>Reddy</surname><given-names>S. G.</given-names></name>; <name><surname>Mao</surname><given-names>X.</given-names></name>; <name><surname>Payne</surname><given-names>A. S.</given-names></name><article-title>Autoreactive IgG and IgA B Cells Evolve through Distinct
Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris</article-title>. <source>Cell Rep</source><year>2018</year>, <volume>24</volume> (<issue>9</issue>), <fpage>2370</fpage>–<lpage>2380</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.093</pub-id>.<pub-id pub-id-type="pmid">30157430</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Fridy</surname><given-names>P. C.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Keegan</surname><given-names>S.</given-names></name>; <name><surname>Thompson</surname><given-names>M. K.</given-names></name>; <name><surname>Nudelman</surname><given-names>I.</given-names></name>; <name><surname>Scheid</surname><given-names>J. F.</given-names></name>; <name><surname>Oeffinger</surname><given-names>M.</given-names></name>; <name><surname>Nussenzweig</surname><given-names>M. C.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Chait</surname><given-names>B. T.</given-names></name>; <name><surname>Rout</surname><given-names>M. P.</given-names></name><article-title>A Robust
Pipeline for Rapid Production
of Versatile Nanobody Repertoires</article-title>. <source>Nat. Methods</source><year>2014</year>, <volume>11</volume> (<issue>12</issue>), <fpage>1253</fpage>–<lpage>1260</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3170</pub-id>.<pub-id pub-id-type="pmid">25362362</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Bondt</surname><given-names>A.</given-names></name>; <name><surname>Hoek</surname><given-names>M.</given-names></name>; <name><surname>Dingess</surname><given-names>K.</given-names></name>; <name><surname>Tamara</surname><given-names>S.</given-names></name>; <name><surname>de Graaf</surname><given-names>B.</given-names></name>; <name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>den Boer</surname><given-names>M. A.</given-names></name>; <name><surname>Damen</surname><given-names>M.</given-names></name>; <name><surname>Zwart</surname><given-names>C.</given-names></name>; <name><surname>Barendregt</surname><given-names>A.</given-names></name>; <name><surname>van Rijswijck</surname><given-names>D. M. H.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Grobben</surname><given-names>M.</given-names></name>; <name><surname>Tejjani</surname><given-names>K.</given-names></name>; <name><surname>van Rijswijk</surname><given-names>J.</given-names></name>; <name><surname>Völlmy</surname><given-names>F.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name>; <name><surname>Fortini</surname><given-names>F.</given-names></name>; <name><surname>Papi</surname><given-names>A.</given-names></name>; <name><surname>Volta</surname><given-names>C. A.</given-names></name>; <name><surname>Campo</surname><given-names>G.</given-names></name>; <name><surname>Contoli</surname><given-names>M.</given-names></name>; <name><surname>van Gils</surname><given-names>M. J.</given-names></name>; <name><surname>Spadaro</surname><given-names>S.</given-names></name>; <name><surname>Rizzo</surname><given-names>P.</given-names></name>; <name><surname>Heck</surname><given-names>A. J. R.</given-names></name><article-title>Into
the Dark Serum Proteome: Personalized
Features of IgG1 and IgA1 Repertoires in Severe COVID-19 Patients</article-title>. <source>Molecular &amp; Cellular Proteomics</source><year>2024</year>, <volume>23</volume> (<issue>1</issue>), <elocation-id>100690</elocation-id><pub-id pub-id-type="doi">10.1016/j.mcpro.2023.100690</pub-id>.<pub-id pub-id-type="pmid">38065436</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>den Boer</surname><given-names>M. A.</given-names></name>; <name><surname>Tamara</surname><given-names>S.</given-names></name>; <name><surname>Mokiem</surname><given-names>N. J.</given-names></name>; <name><surname>van der
Lans</surname><given-names>S. P. A.</given-names></name>; <name><surname>Bondt</surname><given-names>A.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Haas</surname><given-names>P.-J.</given-names></name>; <name><surname>Minnema</surname><given-names>M. C.</given-names></name>; <name><surname>Rooijakkers</surname><given-names>S. H. M.</given-names></name>; <name><surname>van Zuilen</surname><given-names>A. D.</given-names></name>; <name><surname>Heck</surname><given-names>A. J. R.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Direct Mass Spectrometry-Based Detection
and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance
from Patient Serum: A Case Study</article-title>. <source>J. Proteome
Res.</source><year>2023</year>, <volume>22</volume> (<issue>9</issue>), <fpage>3022</fpage>–<lpage>3028</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.3c00330</pub-id>.<pub-id pub-id-type="pmid">37499263</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Bondt</surname><given-names>A.</given-names></name>; <name><surname>Hoek</surname><given-names>M.</given-names></name>; <name><surname>Tamara</surname><given-names>S.</given-names></name>; <name><surname>de Graaf</surname><given-names>B.</given-names></name>; <name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>van Rijswijck</surname><given-names>D. M. H.</given-names></name>; <name><surname>den Boer</surname><given-names>M. A.</given-names></name>; <name><surname>Greisch</surname><given-names>J. F.</given-names></name>; <name><surname>Varkila</surname><given-names>M. R. J.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name>; <name><surname>Cremer</surname><given-names>O. L.</given-names></name>; <name><surname>Bonten</surname><given-names>M. J. M.</given-names></name>; <name><surname>Heck</surname><given-names>A. J. R.</given-names></name><article-title>Human Plasma
IgG1 Repertoires Are Simple, Unique, and
Dynamic</article-title>. <source>Cell Syst</source><year>2021</year>, <volume>12</volume> (<issue>12</issue>), <fpage>1131</fpage>–<lpage>1143</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2021.08.008</pub-id>.<pub-id pub-id-type="pmid">34613904</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Tran</surname><given-names>N. H.</given-names></name>; <name><surname>Rahman</surname><given-names>M. Z.</given-names></name>; <name><surname>He</surname><given-names>L.</given-names></name>; <name><surname>Xin</surname><given-names>L.</given-names></name>; <name><surname>Shan</surname><given-names>B.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name><article-title>Complete De Novo Assembly of Monoclonal
Antibody Sequences</article-title>. <source>Sci. Rep</source><year>2016</year>, <volume>6</volume> (<issue>1</issue>), <fpage>31730</fpage><pub-id pub-id-type="doi">10.1038/srep31730</pub-id>.<pub-id pub-id-type="pmid">27562653</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Sousa</surname><given-names>E.</given-names></name>; <name><surname>Olland</surname><given-names>S.</given-names></name>; <name><surname>Shih</surname><given-names>H. H.</given-names></name>; <name><surname>Marquette</surname><given-names>K.</given-names></name>; <name><surname>Martone</surname><given-names>R.</given-names></name>; <name><surname>Lu</surname><given-names>Z.</given-names></name>; <name><surname>Paulsen</surname><given-names>J.</given-names></name>; <name><surname>Gill</surname><given-names>D.</given-names></name>; <name><surname>He</surname><given-names>T.</given-names></name><article-title>Primary Sequence Determination of
a Monoclonal Antibody against α-Synuclein
Using a Novel Mass Spectrometry-Based Approach</article-title>. <source>Int. J. Mass Spectrom.</source><year>2012</year>, <volume>312</volume>, <fpage>61</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijms.2011.05.005</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Sen</surname><given-names>K. I.</given-names></name>; <name><surname>Tang</surname><given-names>W. H.</given-names></name>; <name><surname>Nayak</surname><given-names>S.</given-names></name>; <name><surname>Kil</surname><given-names>Y. J.</given-names></name>; <name><surname>Bern</surname><given-names>M.</given-names></name>; <name><surname>Ozoglu</surname><given-names>B.</given-names></name>; <name><surname>Ueberheide</surname><given-names>B.</given-names></name>; <name><surname>Davis</surname><given-names>D.</given-names></name>; <name><surname>Becker</surname><given-names>C.</given-names></name><article-title>Automated
Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery</article-title>. <source>J. Am. Soc. Mass Spectrom.</source><year>2017</year>, <volume>28</volume> (<issue>5</issue>), <fpage>803</fpage>–<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1007/s13361-016-1580-0</pub-id>.<pub-id pub-id-type="pmid">28105549</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Rickert</surname><given-names>K. W.</given-names></name>; <name><surname>Grinberg</surname><given-names>L.</given-names></name>; <name><surname>Woods</surname><given-names>R. M.</given-names></name>; <name><surname>Wilson</surname><given-names>S.</given-names></name>; <name><surname>Bowen</surname><given-names>M. A.</given-names></name>; <name><surname>Baca</surname><given-names>M.</given-names></name><article-title>Combining Phage Display
with de Novo Protein Sequencing for Reverse
Engineering of Monoclonal Antibodies</article-title>. <source>MAbs</source><year>2016</year>, <volume>8</volume> (<issue>3</issue>), <fpage>501</fpage>–<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1080/19420862.2016.1145865</pub-id>.<pub-id pub-id-type="pmid">26852694</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Savidor</surname><given-names>A.</given-names></name>; <name><surname>Barzilay</surname><given-names>R.</given-names></name>; <name><surname>Elinger</surname><given-names>D.</given-names></name>; <name><surname>Yarden</surname><given-names>Y.</given-names></name>; <name><surname>Lindzen</surname><given-names>M.</given-names></name>; <name><surname>Gabashvili</surname><given-names>A.</given-names></name>; <name><surname>Adiv Tal</surname><given-names>O.</given-names></name>; <name><surname>Levin</surname><given-names>Y.</given-names></name><article-title>Database-Independent
Protein Sequencing (DiPS) Enables Full-Length de Novo Protein and
Antibody Sequence Determination</article-title>. <source>Molecular &amp;
Cellular Proteomics</source><year>2017</year>, <volume>16</volume> (<issue>6</issue>), <fpage>1151</fpage>–<lpage>1161</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.O116.065417</pub-id>.<pub-id pub-id-type="pmid">28348172</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Pronker</surname><given-names>M. F.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Mass Spectrometry-Based <italic>De
Novo</italic> Sequencing of Monoclonal Antibodies Using Multiple Proteases
and a Dual Fragmentation Scheme</article-title>. <source>J. Proteome
Res.</source><year>2021</year>, <volume>20</volume> (<issue>7</issue>), <fpage>3559</fpage>–<lpage>3566</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.1c00169</pub-id>.<pub-id pub-id-type="pmid">34121409</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Guthals</surname><given-names>A.</given-names></name>; <name><surname>Gan</surname><given-names>Y.</given-names></name>; <name><surname>Murray</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Stinson</surname><given-names>J.</given-names></name>; <name><surname>Nakamura</surname><given-names>G.</given-names></name>; <name><surname>Lill</surname><given-names>J. R.</given-names></name>; <name><surname>Sandoval</surname><given-names>W.</given-names></name>; <name><surname>Bandeira</surname><given-names>N.</given-names></name><article-title>De Novo MS/MS Sequencing
of Native Human Antibodies</article-title>. <source>J. Proteome Res.</source><year>2017</year>, <volume>16</volume> (<issue>1</issue>), <fpage>45</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00608</pub-id>.<pub-id pub-id-type="pmid">27779884</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Cheung</surname><given-names>W. C.</given-names></name>; <name><surname>Beausoleil</surname><given-names>S. A.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Sato</surname><given-names>S.</given-names></name>; <name><surname>Schieferl</surname><given-names>S. M.</given-names></name>; <name><surname>Wieler</surname><given-names>J. S.</given-names></name>; <name><surname>Beaudet</surname><given-names>J. G.</given-names></name>; <name><surname>Ramenani</surname><given-names>R. K.</given-names></name>; <name><surname>Popova</surname><given-names>L.</given-names></name>; <name><surname>Comb</surname><given-names>M. J.</given-names></name>; <name><surname>Rush</surname><given-names>J.</given-names></name>; <name><surname>Polakiewicz</surname><given-names>R. D.</given-names></name><article-title>A Proteomics
Approach for the Identification and Cloning of Monoclonal Antibodies
from Serum</article-title>. <source>Nat. Biotechnol.</source><year>2012</year>, <volume>30</volume> (<issue>5</issue>), <fpage>447</fpage>–<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2167</pub-id>.<pub-id pub-id-type="pmid">22446692</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Castellana</surname><given-names>N. E.</given-names></name>; <name><surname>McCutcheon</surname><given-names>K.</given-names></name>; <name><surname>Pham</surname><given-names>V. C.</given-names></name>; <name><surname>Harden</surname><given-names>K.</given-names></name>; <name><surname>Nguyen</surname><given-names>A.</given-names></name>; <name><surname>Young</surname><given-names>J.</given-names></name>; <name><surname>Adams</surname><given-names>C.</given-names></name>; <name><surname>Schroeder</surname><given-names>K.</given-names></name>; <name><surname>Arnott</surname><given-names>D.</given-names></name>; <name><surname>Bafna</surname><given-names>V.</given-names></name>; <name><surname>Grogan</surname><given-names>J. L.</given-names></name>; <name><surname>Lill</surname><given-names>J. R.</given-names></name><article-title>Resurrection
of a Clinical Antibody: Template Proteogenomic de Novo Proteomic Sequencing
and Reverse Engineering of an Anti-lymphotoxin-α Antibody</article-title>. <source>Proteomics</source><year>2011</year>, <volume>11</volume> (<issue>3</issue>), <fpage>395</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1002/pmic.201000487</pub-id>.<pub-id pub-id-type="pmid">21268269</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Bandeira</surname><given-names>N.</given-names></name>; <name><surname>Pham</surname><given-names>V.</given-names></name>; <name><surname>Pevzner</surname><given-names>P.</given-names></name>; <name><surname>Arnott</surname><given-names>D.</given-names></name>; <name><surname>Lill</surname><given-names>J. R.</given-names></name><article-title>Automated
de Novo Protein Sequencing of Monoclonal Antibodies</article-title>. <source>Nat. Biotechnol.</source><year>2008</year>, <volume>26</volume> (<issue>12</issue>), <fpage>1336</fpage>–<lpage>1338</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1208-1336</pub-id>.<pub-id pub-id-type="pmid">19060866</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Giesbers</surname><given-names>K. C.</given-names></name>; <name><surname>Šiborová</surname><given-names>M.</given-names></name>; <name><surname>Beugelink</surname><given-names>J. W.</given-names></name>; <name><surname>Pronker</surname><given-names>M. F.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Hilkens</surname><given-names>J.</given-names></name>; <name><surname>Janssen</surname><given-names>B. J.</given-names></name>; <name><surname>Strijbis</surname><given-names>K.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Reverse-Engineering
the Anti-MUC1
Antibody 139H2 by Mass Spectrometry–Based de Novo Sequencing</article-title>. <source>Life Sci. Alliance</source><year>2024</year>, <volume>7</volume> (<issue>6</issue>), <elocation-id>e202302366</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.202302366</pub-id>.<pub-id pub-id-type="pmid">38508723</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Template-Based
Assembly of Proteomic
Short Reads For <italic>De Novo</italic> Antibody Sequencing and Repertoire
Profiling</article-title>. <source>Anal. Chem.</source><year>2022</year>, <volume>94</volume> (<issue>29</issue>), <fpage>10391</fpage>–<lpage>10399</lpage>. <pub-id pub-id-type="doi">10.1021/acs.analchem.2c01300</pub-id>.<pub-id pub-id-type="pmid">35834437</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>Giesbers</surname><given-names>K. C. A. P.</given-names></name>; <name><surname>Šiborová</surname><given-names>M.</given-names></name>; <name><surname>Beugelink</surname><given-names>J. W.</given-names></name>; <name><surname>Pronker</surname><given-names>M. F.</given-names></name>; <name><surname>Schulte</surname><given-names>D.</given-names></name>; <name><surname>Hilkens</surname><given-names>J.</given-names></name>; <name><surname>Janssen</surname><given-names>B. J. C.</given-names></name>; <name><surname>Strijbis</surname><given-names>K.</given-names></name>; <name><surname>Snijder</surname><given-names>J.</given-names></name><article-title>Reverse Engineering the Anti-MUC1
Hybridoma Antibody 139H2 by Mass Spectrometry-Based de Novo Sequencing</article-title>. <source>bioRxiv</source><year>2023</year>, <pub-id pub-id-type="doi">10.1101/2023.07.05.547778</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Ivanov</surname><given-names>D. G.</given-names></name>; <name><surname>Ivetic</surname><given-names>N.</given-names></name>; <name><surname>Du</surname><given-names>Y.</given-names></name>; <name><surname>Nguyen</surname><given-names>S. N.</given-names></name>; <name><surname>Le</surname><given-names>S. H.</given-names></name>; <name><surname>Favre</surname><given-names>D.</given-names></name>; <name><surname>Nazy</surname><given-names>I.</given-names></name>; <name><surname>Kaltashov</surname><given-names>I. A.</given-names></name><article-title>Reverse
Engineering of a Pathogenic Antibody Reveals the Molecular Mechanism
of Vaccine-Induced Immune Thrombotic Thrombocytopenia</article-title>. <source>J. Am. Chem. Soc.</source><year>2023</year>, <volume>145</volume> (<issue>46</issue>), <fpage>25203</fpage>–<lpage>25213</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.3c07846</pub-id>.<pub-id pub-id-type="pmid">37949820</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Guthals</surname><given-names>A.</given-names></name>; <name><surname>Clauser</surname><given-names>K. R.</given-names></name>; <name><surname>Bandeira</surname><given-names>N.</given-names></name><article-title>Shotgun Protein
Sequencing with Meta-Contig
Assembly</article-title>. <source>Molecular &amp; Cellular Proteomics</source><year>2012</year>, <volume>11</volume> (<issue>10</issue>), <fpage>1084</fpage>–<lpage>1096</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M111.015768</pub-id>.<pub-id pub-id-type="pmid">22798278</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="undeclared" id="cit31"><person-group person-group-type="allauthors"><name><surname>Yilmaz</surname><given-names>M.</given-names></name>; <name><surname>Fondrie</surname><given-names>W. E.</given-names></name>; <name><surname>Bittremieux</surname><given-names>W.</given-names></name>; <name><surname>Oh</surname><given-names>S.</given-names></name>; <name><surname>Noble</surname><given-names>W. S.</given-names></name></person-group><source>De Novo Mass Spectrometry Peptide
Sequencing with a Transformer Model</source>. <publisher-name>PMLR
June</publisher-name><volume>28</volume>, <year>2022</year>; pp <fpage>25514</fpage>–<lpage>25522</lpage>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://proceedings.mlr.press/v162/yilmaz22a.html">https://proceedings.mlr.press/v162/yilmaz22a.html</uri> (accessed 2024–01–30).</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Yilmaz</surname><given-names>M.</given-names></name>; <name><surname>Fondrie</surname><given-names>W. E.</given-names></name>; <name><surname>Bittremieux</surname><given-names>W.</given-names></name>; <name><surname>Nelson</surname><given-names>R.</given-names></name>; <name><surname>Ananth</surname><given-names>V.</given-names></name>; <name><surname>Oh</surname><given-names>S.</given-names></name>; <name><surname>Noble</surname><given-names>W. S.</given-names></name>; <name><surname>Allen</surname><given-names>P. G.</given-names></name><article-title>Sequence-to-Sequence Translation
from Mass Spectra to Peptides with a Transformer Model</article-title>. <source>bioRxiv</source><year>2023</year>, <pub-id pub-id-type="doi">10.1101/2023.01.03.522621</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Gutenbrunner</surname><given-names>P.</given-names></name>; <name><surname>Kyriakidou</surname><given-names>P.</given-names></name>; <name><surname>Welker</surname><given-names>F.</given-names></name>; <name><surname>Cox</surname><given-names>J.</given-names></name><article-title>Spectrum Graph-Based
de-Novo Sequencing Algorithm MaxNovo Achieves High Peptide Identification
Rates in Collisional Dissociation MS/MS Spectra</article-title>. <source>bioRxiv</source><year>2021</year>, <pub-id pub-id-type="doi">10.1101/2021.09.04.458985</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Ma</surname><given-names>B.</given-names></name><article-title>Novor: Real-Time
Peptide de Novo Sequencing Software</article-title>. <source>J. Am.
Soc. Mass Spectrom.</source><year>2015</year>, <volume>26</volume> (<issue>11</issue>), <fpage>1885</fpage>–<lpage>1894</lpage>. <pub-id pub-id-type="doi">10.1007/s13361-015-1204-0</pub-id>.<pub-id pub-id-type="pmid">26122521</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Tran</surname><given-names>N. H.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Xin</surname><given-names>L.</given-names></name>; <name><surname>Shan</surname><given-names>B.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name><article-title>De Novo Peptide
Sequencing by Deep Learning</article-title>. <source>Proc. Natl. Acad.
Sci. U. S. A.</source><year>2017</year>, <volume>114</volume> (<issue>31</issue>), <fpage>8247</fpage>–<lpage>8252</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1705691114</pub-id>.<pub-id pub-id-type="pmid">28720701</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Chi</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>He</surname><given-names>K.</given-names></name>; <name><surname>Wu</surname><given-names>L.</given-names></name>; <name><surname>Yang</surname><given-names>B.</given-names></name>; <name><surname>Sun</surname><given-names>R.-X.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Zeng</surname><given-names>W.-F.</given-names></name>; <name><surname>Song</surname><given-names>C.-Q.</given-names></name>; <name><surname>He</surname><given-names>S.-M.</given-names></name>; <name><surname>Dong</surname><given-names>M.-Q.</given-names></name><article-title>pNovo+: De Novo
Peptide Sequencing
Using Complementary HCD and ETD Tandem Mass Spectra</article-title>. <source>J. Proteome Res.</source><year>2013</year>, <volume>12</volume> (<issue>2</issue>), <fpage>615</fpage>–<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1021/pr3006843</pub-id>.<pub-id pub-id-type="pmid">23272783</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Chi</surname><given-names>H.</given-names></name>; <name><surname>Sun</surname><given-names>R.-X.</given-names></name>; <name><surname>Yang</surname><given-names>B.</given-names></name>; <name><surname>Song</surname><given-names>C.-Q.</given-names></name>; <name><surname>Wang</surname><given-names>L.-H.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Fu</surname><given-names>Y.</given-names></name>; <name><surname>Yuan</surname><given-names>Z.-F.</given-names></name>; <name><surname>Wang</surname><given-names>H.-P.</given-names></name>; <name><surname>He</surname><given-names>S.-M.</given-names></name>; <name><surname>Dong</surname><given-names>M.-Q.</given-names></name><article-title>pNovo: <italic>De Novo</italic> Peptide Sequencing
and Identification Using HCD Spectra</article-title>. <source>J. Proteome
Res.</source><year>2010</year>, <volume>9</volume> (<issue>5</issue>), <fpage>2713</fpage>–<lpage>2724</lpage>. <pub-id pub-id-type="doi">10.1021/pr100182k</pub-id>.<pub-id pub-id-type="pmid">20329752</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Chi</surname><given-names>H.</given-names></name>; <name><surname>Zhou</surname><given-names>W.-J.</given-names></name>; <name><surname>Zeng</surname><given-names>W.-F.</given-names></name>; <name><surname>He</surname><given-names>K.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Sun</surname><given-names>R.-X.</given-names></name>; <name><surname>He</surname><given-names>S.-M.</given-names></name><article-title>Open-pNovo: De Novo Peptide Sequencing
with Thousands of Protein Modifications</article-title>. <source>J.
Proteome Res.</source><year>2017</year>, <volume>16</volume> (<issue>2</issue>), <fpage>645</fpage>–<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00716</pub-id>.<pub-id pub-id-type="pmid">28019094</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="journal" id="cit39"><name><surname>Needleman</surname><given-names>S. B.</given-names></name>; <name><surname>Wunsch</surname><given-names>C. D.</given-names></name><article-title>A General Method Applicable to the
Search for Similarities
in the Amino Acid Sequence of Two Proteins</article-title>. <source>J. Mol. Biol.</source><year>1970</year>, <volume>48</volume> (<issue>3</issue>), <fpage>443</fpage>–<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1016/0022-2836(70)90057-4</pub-id>.<pub-id pub-id-type="pmid">5420325</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Smith</surname><given-names>T. F.</given-names></name>; <name><surname>Waterman</surname><given-names>M. S.</given-names></name><article-title>Comparison of Biosequences</article-title>. <source>Adv.
Appl. Math</source><year>1981</year>, <volume>2</volume> (<issue>4</issue>), <fpage>482</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1016/0196-8858(81)90046-4</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Henikoff</surname><given-names>S.</given-names></name>; <name><surname>Henikoff</surname><given-names>J. G.</given-names></name><article-title>Amino Acid Substitution Matrices
from Protein Blocks</article-title>. <source>Proc. Natl. Acad. Sci.
U. S. A.</source><year>1992</year>, <volume>89</volume> (<issue>22</issue>), <fpage>10915</fpage>–<lpage>10919</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.89.22.10915</pub-id>.<pub-id pub-id-type="pmid">1438297</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="journal" id="cit42"><name><surname>Johnson</surname><given-names>R. S.</given-names></name>; <name><surname>Martin</surname><given-names>S. A.</given-names></name>; <name><surname>Biemann</surname><given-names>K.</given-names></name><article-title>Collision-Induced Fragmentation
of
(M + H)+ Ions of Peptides. Side Chain Specific Sequence Ions</article-title>. <source>Int. J. Mass Spectrom Ion Process</source><year>1988</year>, <volume>86</volume>, <fpage>137</fpage>–<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/0168-1176(88)80060-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Bouwmeester</surname><given-names>R.</given-names></name>; <name><surname>Gabriels</surname><given-names>R.</given-names></name>; <name><surname>Hulstaert</surname><given-names>N.</given-names></name>; <name><surname>Martens</surname><given-names>L.</given-names></name>; <name><surname>Degroeve</surname><given-names>S.</given-names></name><article-title>DeepLC Can
Predict Retention Times for Peptides That Carry As-yet Unseen Modifications</article-title>. <source>Nat. Methods</source><year>2021</year>, <volume>18</volume> (<issue>11</issue>), <fpage>1363</fpage>–<lpage>1369</lpage>. <pub-id pub-id-type="doi">10.1038/s41592-021-01301-5</pub-id>.<pub-id pub-id-type="pmid">34711972</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="journal" id="cit44"><name><surname>Sinitcyn</surname><given-names>P.</given-names></name>; <name><surname>Hamzeiy</surname><given-names>H.</given-names></name>; <name><surname>Salinas
Soto</surname><given-names>F.</given-names></name>; <name><surname>Itzhak</surname><given-names>D.</given-names></name>; <name><surname>McCarthy</surname><given-names>F.</given-names></name>; <name><surname>Wichmann</surname><given-names>C.</given-names></name>; <name><surname>Steger</surname><given-names>M.</given-names></name>; <name><surname>Ohmayer</surname><given-names>U.</given-names></name>; <name><surname>Distler</surname><given-names>U.</given-names></name>; <name><surname>Kaspar-Schoenefeld</surname><given-names>S.</given-names></name>; <name><surname>Prianichnikov</surname><given-names>N.</given-names></name>; <name><surname>Yılmaz</surname><given-names>Ş.</given-names></name>; <name><surname>Rudolph</surname><given-names>J. D.</given-names></name>; <name><surname>Tenzer</surname><given-names>S.</given-names></name>; <name><surname>Perez-Riverol</surname><given-names>Y.</given-names></name>; <name><surname>Nagaraj</surname><given-names>N.</given-names></name>; <name><surname>Humphrey</surname><given-names>S. J.</given-names></name>; <name><surname>Cox</surname><given-names>J.</given-names></name><article-title>MaxDIA Enables
Library-Based
and Library-Free Data-Independent Acquisition Proteomics</article-title>. <source>Nat. Biotechnol.</source><year>2021</year>, <volume>39</volume> (<issue>12</issue>), <fpage>1563</fpage>–<lpage>1573</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-021-00968-7</pub-id>.<pub-id pub-id-type="pmid">34239088</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
